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Cellular microenvironment or cell niche plays an important role in developmental biology and
disease pathophysiology. Physical or chemical signals in microenvironment drive the cellular activity.
These signaling molecules are generated from the surrounding cells/tissues as part of intercellular
communication; a fundamental property of a cell. Dynamic profile of these signaling molecules in the
microenvironment plays a pivotal role in transfer of molecular information from cell to cell in disease
proliferation or fate determination. Recapitulating these signaling cues in an in vitro study is difficult to
achieve using standard cell culture techniques. However microfluidic systems are capable of addressing
these issues, due to their ability to precisely control the microenvironment.
The first study focuses on developing a microfluidic system capable of differentiating MNs in a 3D
microenvironment (similar to in vivo) and perform a drug assay to identify the therapeutic concentration
range. Using this microfluidic device, ALS (amyotrophic lateral sclerosis) motor neurons were
differentiated (in 3D) and ideal concentration of rapamycin in rescuing motor neurons from degeneration
was identified.
In the second study, a gradient generating coculture system capable of culturing two distinct types
of tissues (in 3D) (muscle and motor neurons) in spatially distinct chambers which were interconnected by
microchannels for intercellular communications (chemical signal and axon transport) was designed and

fabricated. This microfluidic device offers us an ability to understand and evaluate the effects of coculturing
muscle cells with motor neurons in defining the motor neuron columnar identity.
Thus, the current micro device will be a useful platform not only in understanding the
developmental processes but also to study and model rare degenerative diseases. Due to its ability to create
concentration gradient, this device can also be a unique platform for scientists to perform a high throughput
screening for drug activity and drug toxicity using patient specific cells.
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CHAPTER 1 : INTRODUCTION
This thesis presents an interdisciplinary research approach to study developmental biology and associated
disease modeling. To study developmental biology and disease modeling, a platform with an acute control
of the microenvironment is necessary to truly represent an in vivo like microenvironment in an in vitro
study. Microfabricated microfluidic technology provides excellent control over the spatial and temporal
chemical environment within a 3D cell culture to accurately emulate in vivo conditions during cell and
tissue development. Therefore, silicon based microfluidic devices are designed, fabricated and employed
to:
a. Differentiate cells in 3D and perform a drug assay to identify the ideal dosage response
range (gradient generating microdevice)
b. Coculture two different types of cells (in 3D) to study the effect of released signaling
molecules from each other on each other (gradient generating “coculture” device)
1.1 Background
1.1.1 In vitro cell culture
In vitro cell culture involves extracting cells from a biological tissue and growing them in a
controlled environment; this was pioneered by Ross Harrison in 19071 while developing a method to keep
the frog neuroblast alive outside the body. After this, the progression and advancement of this technique
increased significantly due to its immense need in various branches of medicinal science, especially in
virology and oncology. The predominantly used method of in vitro cell culture is monolayer cell culture
(2D). Here cells were cultured on a treated surface or in a tissue culture dish as an adherent monolayer of
cells. However, the 2D cell culture does not represent the morphology2,3 of the in vivo tissue. Absence of
the 3D morphology and organization in a 2D culture affects cell signaling4,5, gene expression 6–8 and cell
interactions9,10. To overcome this and achieve an in vivo like cellular organization and complexity, a 3D
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Fincell culture model was being widely adopted to research in cell and tissue biology 11–14. 3D cell culture
can be divided into suspension culture and scaffold-based culture. Suspension culture involves culturing
cells in a culture media, whereas scaffold-based cell culture involves the use of a supporting matrix
(Matrigelä, collagen, agarose, laminin, etc..,) to culture cells. The type of 3D culture to use was usually
based on the cells involved and the parameters of the study15. Numerous studies16–20 with different cell types
have indicated physiologically relevant21,22 events in 3D cultures compared to 2D. Apart from 3D cell
culture, two other prominent fields that have impacted the advancement of in vitro studies were stem cell
culture and microfluidics.
Stem cells are unspecialized cells that can differentiate into any type of cell of an organism and are
also capable of self-renewal. Stem cells can be classified into pluripotent, multipotent and unipotent based
on the spectrum of cells that can be differentiated. Pluripotent being the topmost in terms of differentiation,
i.e., they can differentiate into any cell, whereas unipotent cells are the bottom most, i.e., they can
differentiate into only one cell type. Stem cells has contributed immensely to tissue engineering23,
regenerative medicine24, cell therapay25 and developmental biology26,27. For example, identification of
retro-virus mediated transduction (transfer of genetic material) of four transcription factors (Oct-3/4, Sox2,
KLF4, and c-Myc) to convert fibroblast (non-pluripotent cells) to pluripotent cells by scientists Yamanaka
and Takahashi28 was a groundbreaking achievement in stem cell therapy. As a result, stem cells become an
invaluable tool for scientists to study in vitro disease modeling29, drug discovery and development
biology30–32. With stem cells innate abilities of self-organization and pluripotency, various in vitro 3D cell
culture models (cells/tissues/organs) were developed to understand various aspects of developmental
biology and pathology33,34. Nevertheless, most current in vitro 3D cell culture methods such as hanging
drop model and spheroid-based cell culture cannot recreate an accurate in vivo microenvironment. For
example, standard cell culture techniques struggle in recreating the dynamic profile of soluble factors
involved in cell differentiation. Another limitation would be its inability to create a suitable environment
and/or platform to study the paracrine signaling between two different cell types.
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With the application of microengineering methods, these limitations can be addressed by using
microfluidics. Microfluidics, a field of engineering which can be applied to achieve precise control over
the chemical microenvironment within a cell culture.
1.1.2 Microfluidics
Microfluidics is a field of engineering involved in controlling and manipulating small volumes of
fluids (10-6 liters - 10-12 liters) in a defined geometry. The field of microfluidics emerged out of the
microsensors and microelectromechanical device (MEMS) fields. The initial work in microfluidics was
applied for developing inkjet nozzels35 which led to the commercialization of inkjet printers. Its potential
for application to the precise and high throughput manipulation of small amounts of chemical fluids was
soon recognized and it was applied to develop microscale chemical and molecular analysis systems. A
microscale gas chromatography system developed by Terry et.al36 in 1979 was widely regarded as the first
“lab-on-chip” or micro-total analysis system (µTAS). With the advancement in microfabrication
technology, the microfluidic field was also explored in different avenues of science and engineering.
However, it was still not economical nor easy to commercialize the microfluidic devices. This changed with
the introduction of poly(dimethyl siloxane) (PDMS) by the Whiteside’s group in early 200037,38. Compared
to the other micromachined materials of the time (glass, silicon, acrylics) PDMS device fabrication was
simpler and more economical. The fabrication of a PDMS microfluidic device involves pouring the uncured
PDMS onto microstructured molds, curing and releasing them, resulting in the replication of miniature
geometries in the PDMS. The molded part was then bonded to a surface (typically glass) to create
microfluidic channels. This method of fabrication is known as soft lithography due to the soft, elastomeric
nature of PDMS39,40. Because the PDMS material itself was relatively inexpensive, the process does not
require specialized or expensive equipment, and the mold can be reused multiple times, the cost of this
procedure is low and readily accessible to anyone. Hence, it was adopted widely and resulted in many
microfluidic device developments and applications. Though it is a widely used material of choice in
designing microfluidic devices, it has both advantages and limitations when applied to cell biology. An
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advantage over other materials, especially solid-state materials, is its high oxygen permeability. However,
on the downside, due to its high hydrophobicity, the surface adsorption of small molecules such as proteins
and signaling molecules poses a significant problem in using PDMS devices in drug discovery, cell culture
and molecular biology41,42. To mitigate this limitation, various surface treatments43,44 of PDMS have been
explored and applied. In comparison to PDMS, silicon and glass based microfluidic devices do not have
the above limitations and have reemerged in recent years as materials of choice for microfluidic devices.
The work presented here utilizes silicon-based microfluidic devices to manipulate the chemical
microenvironment inside 3D cell cultures in the performance of two experimental studies. The background,
motivation and general approach for each are introduced in this chapter. The experimental materials,
methods and results for each study are presented in subsequent chapters.
1.1.2.1 Gradient generating microfluidic device for drug assay to rescue ALS motor neurons
In a human body the concentration gradients of biomolecules control various functions such as
immune response45,46, tissue development47–49, wound healing50–52, cancer metastasis53,54, etc. In an in vitro
study, the generation of these concentration gradients can be achieved with microfluidic systems. The more
common designs of gradient generators from Whiteside55,56 and other groups47,57 concentrated on a physical
phenomenon called laminar flow for gradient generation. This method of gradient generation involves the
introduction of two adjacent streams of different chemicals where the incoming streams were split and
combined multiple times to generate the diffusion profile. The microfluidic design of these gradient
generators looks like a “Christmas tree”. This design was successfully used in various studies ranging from
chemotaxis58 of bacteria to drug dosage59 dependence in nerve regeneration. However, the cells cultures in
study were subjected to constant flow, which does not truly represent the in vivo microenvironment of most
tissues, with a most notable exception being blood vessels. To avoid this, scientists used membranes60,61 to
separate and protect the cells from the shear stress due to fluid flow. This overcame the limitations of
constant flow exposure but involves a time-intensive microfabrication process. Application of gradient
generating microdevices was identified early on as a means for performing high throughput drug screening
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62–64

and drug development65,66 by exposing a single culture to a range of drug concentrations or a

combination of many drugs. Moreover, gradient generating microfluidic devices capable of controlling the
microenvironment in 3D stem cell cultures can act as a bridge between animal testing and human trials.
Therefore, to provide a more realistic in vivo environment for cells in culture, a source and sink model of
gradient generator (Figure 1), which is easy to fabricate and does not subject the cell to direct fluid flow,
was adopted in this work to study the effect of the drug (rapamycin) in rescuing amyotrophic lateral
sclerosis (ALS) motor neurons (MNs) from degeneration (chapter 2).

Figure 1: Gradient generator (source and sink model)
A gradient generating microdevice with source and sink model. Cells were not exposed to the fluid flow,
but rather media components enter the cell culture chamber by diffusing through the small opening (vias),
in a manner similar to nutrient diffusion from blood capillary beds to the center of tissue mass.
Motor neurons are specialized cells whose cell bodies (soma) reside in the spinal cord and brain,
whereas their extensions/processes extend all over the body. They are involved in the signal transmission
from the brain to the target muscle/glands (control voluntary/involuntary actions). MNs are an essential
element for the proper functioning of the human body.
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ALS, a progressive degenerative MN disease causing degeneration of both upper and lower motor
neurons, eventually leading to muscle atrophy and death67. Mutations68 in two genes SOD169 (Superoxide
dismutase-1)70 and TDP-43 (TAR DNA-binding protein-43)71 were identified as the defining pathologies
for familial and sporadic ALS. The mutation in the TDP-43 gene results in the formation of non-nuclear
aggregates of TDP-43, which cause ALS onset and progression72. The cause of these aggregate formation
varies from patient to patient (example: abnormal C-terminal end of TDP-43 fragment73,74 or unwarranted
post-translational protein modification75–78). These changes result in the loss of TDP-4376,79,80 function as a
nuclear protein and also increase the cytosolic toxicity due to the mislocated TDP-4381–84. Mislocalization
of another DNA binding nuclear protein called Fused in Sarcoma (FUS) was identified as one of the casual
factor ALS pathology85,86. Presence of mislocalized cytoplasmic aggregates of TDP-4387 and FUS88 can be
used as pathological disease markers of ALS and also as a target for therapeutic remediation.
Rapamycin, a widely used mTOR signaling (the mechanistic target for rapamycin) inhibitor, has
been suggested as a potential therapeutic in remediation for ALS89,90. Rapamycin activates autophagy91 by
inhibiting the mTOR signaling pathway92. Autophagy, a cellular process involved in clearing unwanted and
abnormal proteins from cells, including mislocalized TDP-43 aggregates. Kamm et al.93 reported increased
muscle contraction in ALS-derived motor units under the influence of rapamycin.
With such promising results everywhere, Dr. Cox's lab was also involved in investigating
rapamycin efficacy in clearing TDP-43 aggregates in MNs with ALS phenotype. They successfully
identified that TDP-43 clearance does occur in a 2D culture of MNs under the influence of rapamycin.
However, with growing consensus over the use of 3D in vitro culture in disease modeling, as 2D cultures
do not genuinely mimic the in vivo morphology and notable difference in drug activity from 3D to 2D94,95,
there was a need for a system capable of exploring dosage-dependent activity of a drug in a 3D culture.
Microfluidic gradient generators have established themselves as a capable system to perform a drug dosage
dependent assay across various biological models96–98. Therefore, in collaboration with Dr.Cox’s lab we
adapted a microfluidic concentration gradient generator (developed by Demers et al.99) to test a range of
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rapamycin concentrations in a single experiment and identify the efficacy and ideal dosage range of
rapamycin in rescuing the ALS MNs from degeneration (chapter-2).
1.1.2.2 Gradient generating coculture device for neural development
Intercellular signaling is a complex process responsible for orchestrating various physiological
processes. Embryonic development is the best example of this complexity, as it is characterized by such
signaling cues (physical and chemical). The factors involved in cell development were rigorously explored
over the years, yet some intricate details are missing on how a cell makes a decision and reproduces the
result from this decision with 100% success every time. The current thesis (chapter 3) focuses on neural
development, especially on factors affecting motor neuron (MN) formation.
The neural tube is a structure formed after the three primary germ layers (endoderm, ectoderm,
mesoderm) and is also the progenitor of the central nervous system (CNS). The anterior part of the neural
tube develops into brain, whereas the posterior region into spinal cord. Differentiation of the spinal cord is
a complex process where different types of cells are differentiated according to the positional identity along
the dorsoventral and anterior-posterior axis. A mesodermal structure called notochord (axial mesoderm)
runs parallel to the neural tube. Notochord along with floor plate (ventral most part of the neural tube) are
involved in secreting sonic hedgehog (Shh)100, a signaling molecule released from the ventral region of the
neural tube, whereas roof plate (endodermal structure) and ectoderm releases bone morphogenic protein
(BMP) and wingless-related integration protein (Wnt ) in the dorsal region of the neural tube (Figure 2b).
This opposing gradient across the dorsoventral axis generates 11 different types of neurons including MNs
(Figure 2b) in the developing spinal cord. Another signaling system across the anterior-posterior axis,
controlled by opposing gradients of retinoic acid (RA)101–103 (in the anterior region) and fibroblast growth
factor (FGF), growth differentiation factor (GDF) & Wnt104,105 (in the posterior region) create a
spatiotemporal positional identity for the ventrally developing motor neurons and differentiate them into
different subtypes (Figure 2a). The gradient across the anterior-posterior axis activates the Hox gene
patterning; a combinatorial code106 of Hox gene expression specifies the columnar and pool identity
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(subtypes of MNs) to the ventrally differentiating MNs. Though the Hox gene patterning is well studied in
the case of MNs, it is still unclear in case of other neurons.

Figure 2: Morphogen gradient across the neural tube
a) Anterior-posterior patterning of MN into different columnar identity. A gradient of FGF, Wnt, and GDF
is present in the posterior region of the neural tube, whereas an opposing gradient of RA is in the anterior
region. b) Cross-section of neural tube with concentration gradients across the dorsoventral axis, generating
dorsal interneuron (dI1-6), ventral neurons (V0-3) and motor neurons at different regions. c) Under
opposing gradients of morphogens, the differentiating somites compartmentalize into two regions, dorsal
(dermomyotome) and ventral (sclerotome), with different progenitor cells. Progenitor cells of dermatome
differentiate into skin, adipose tissue; myotome into muscle cells and sclerotome into skeleton and cartilage.
LMC (lateral motor column), MMC (median motor column), HMC (hypaxial motor column), PGC
(preganglionic motor column), roof plate (RP), floor plate (FP), notochord (NC). (source for the gradient
107–109
generation images
).

Concurrent with neural development, muscle development begins in the somites. Somites are
segmented structures flanking the neural tube and are derived from the paraxial mesoderm (mesodermal
structure). The segmentation of paraxial mesoderm into somites is controlled by in-built oscillating Notch
and FGF signaling110,111. As the segmentation of paraxial mesoderm into somites is carried out in the
anterior-posterior axis, the newly formed somites simultaneously undergo compartmentalization in the
dorsoventral axis. Compartmentalization (Figure 2c) of somites into dorsal dermatome, myotome and

8

ventral sclerotome occur under the opposing gradient of Shh, noggin (from the notochord and neural tube)
Wnt and BMP (from roof plate and ectoderm) 112. BMP promotes the formation of lateral and intermediate
mesoderm (mesodermal structures) and also has an inhibitory effect on myogenesis (formation of muscle
cells). To avoid the BMP activity on somites differentiation, dorsal somite cells locally produce noggin to
inhibit high BMP gradients from the roof plate and ectoderm. At the same time, the noggin from the
notochord and neural tube inhibits BMP’s effect of lateralization in the ventral region of somites.
Myogenesis is divided into two phases i.e., primary phase and secondary phase. In primary phase
Pax3+/Pax7+ progenitor cells113,114 from dermomyotome migrate and form myotome (the layer between
dermatome and sclerotome). These progenitor cells differentiate into primary myocytes and myofibres
expressing slow myosin heavy chain (slow MyHC) and myosin light chain 1 (MyLC1) proteins, these form
the template upon which the adult muscles tissues are built115,116. During the second phase of myogenesis
the progenitor cells with downregulated Pax3 and upregulated Pax7 differentiate into myocytes and fuse
with each other or with primary myofibres and form muscle tissue. These secondary myofibers express βenolase, myosin light chain 3 (MyLC3) and fast myosin heavy chain (fast MyHC) proteins. Based on the
gene expressions under the influence of the opposing gradient, the progenitor cells from the dermomyotome
(dermatome and myotome) also differentiate into brown fat and dermis, whereas cells from sclerotome
differentiate into vertebrae, rib cartilage and part of the occipital bone. Though a feeble attempt to explain
the background of muscle differentiation was endeavored, this does not portray a complete picture of
muscle differentiation, as the complexity and the number of signaling molecules involved are enormous.
A completed neural circuit involves neuromuscular junction formation, but how do these
differentiated MNs know to identify the right target? It is still unclear how neurons identify their target
without any mismatch, but the most accepted model is that the tip of the growing axons of a differentiated
MN have guidance receptors (attractive and repulsive)117. A myriad of chemical cues from various tissues
navigates the axons guiding them to reach their target. However, how many cues are involved in guiding
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the 80 billion neurons is an answer that has startled the scientists and has been a puzzling unanswered
question118.
In vitro studies to understand the cell-cell signaling or effect of different tissues on each other was
always challenging due to the absence of a proper platform to study. With the advent of microfluidics, this
has been averted as coculture microsystems were extensively used to understand the cancer metastasis119,
drug toxicity120, intercellular communications121, paracrine signaling122 and neurobiology123–125. However,
using a microfluidic system to study developmental biology was seldomly attempted; moreover, using a
coculture microfluidic system to understand the neural developmental aspects was never attempted. Though
the current model of neuromuscular development suggests being independent115,126 of each other, the
complex orchestra of overlapping signaling pathways/cues (FGF, Shh, GDF, Wnt, BMP, etc..) and a lot of
unanswered questions suggest a possibility of being the opposite. Therefore, the current thesis (chapter 3)
presents an attempt to use microfluidic device to coculture skeletal muscle and MNs and understand the
effect of skeletal muscles on differentiating motor neurons.
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CHAPTER 2 : DRUG ASSAY IN A MICROFLUIDIC DEVICE
2.1 Introduction
Microfluidics has recently surfaced as an invaluable technique for cell culturing. One of the more
significant advancements in microfluidics came with the advent of the concentration gradient generator,
originally proposed by Whiteside’s56 and significantly refined by Demer’s99,127. Not only do gradient
generators provide more facile, realistic, and meaningful bio environments for cellular studies, they can
also provide custom spatial and temporal landscapes mimicking complex in vivo environments. This is an
unique advantage of microfluidic systems that is not easily available using traditional cell plating techniques
and therefore they provide a meaningful answer to previously intractable biological questions99,128.
Microfluidics has since been incorporated successfully in many cell culture applications, including singlecell analysis, developmental studies, pharmacologic interventions, and precision medicine129–131.
In this chapter we recruit a microfluidics gradient generator designed by Demer’s99 et al. to explore
a) Efficacy of anti-cancer drugs in arresting the propagation of 3D cultured U2OS (Osteosarcoma)
cells and to identify the effective concentration range for cancer treatment.
Osteosarcoma is a most common bone cancers which is predominant in children and
teen132. U2OS cells were osteosarcoma cell lines generated from the bone tissue of teen suffering
from osteosarcoma. 2D cell culture of cell lines has been the predominant method since 1900 for
in vitro studies but it has its limitation to mimic the in vivo environment and physiology133. 3D
culture overcomes this limitation and helps to mimic the in vivo system134. With this advancement,
3D in vitro tumor studies became the preferred method for many biologists compared to 2D in vitro
tumor studies. This study presents a microfluidic system to culture osteosarcoma cells in 3D and to
identify the concentration dependent cell viability assay from a single device. The 3D microfluidic
system provides a platform to culture cells in 3D and expose the cultured cells to anti-cancer drugs
in a fashion that truly represents in vivo drug treatment. Thereby this platform can be used to
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carefully understand the pharmacodynamics and tumor physiology with the ability to monitor and
modify the conditions independently.
b) Linear rapamycin concentration gradient across a 3D motor neuron culture and map the permissive
zones of motor neuron survival to evaluate the efficacy of rapamycin therapeutics in ALS.
Motor neurons (MN) are specialized cells involved in the voluntary and involuntary
movements. Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease leading
to muscle atrophy and death67. A common defining hallmark of ALS69 is, mutations in superoxide
dismutase 1 (SOD1) gene70 involved in production superoxide dismutase enzyme (which break
downs and clear superoxide radicals), and TAR DNA-binding protein-43 (TDP-43) gene, resulting
in formation in the cytoplasmic aggregates 71. Rapamycin, or sirolimus, has been suggested as a
potential therapeutic remediation for ALS89,90, and is widely used to inhibit mTOR signaling (the
mechanistic target for rapamycin). In this chapter we recruit microfluidics to generate a linear
rapamycin concentration gradient across a 3D MN culture and map the permissive zones of MN
survival to evaluate the efficacy of rapamycin therapeutics in ALS and compare the data to
traditional 2D MN culture.
2.2 Materials and methods
All cell culture and differentiation in the device were carried out at 370C under 5% CO2.
2.2.1 U2OS cell culture
U-2 OS (ATCC HTB-96) cells were acquired from ATCC (American Type Culture Collection).
Cells were plated in the 60 mm cell culture dishes and allowed to grow for 2 to 3 days for 80% confluency
in U2OS media (Table 1).
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2.2.2 Expansion and cryopreservation
Expanded U2OS were cryopreserved by mixing the cells with 10% DMSO and U2OS media and
freezing them at -80 oC (overnight) using a freezing container (rate of cooling approx -1°C/minute ). Vials
are transferred from the -80 freezer to liquid nitrogen dewar the next day and preserved till the day of use.
2.2.3 U2OS culture in microdevice
On the day of the microdevice experiment, U2OS from 60 mm dish were trypsinized (1 ml of 0.25%
trypsin- 0.03% EDTA solution for 3 -5 mins till the cells detach from the plate and add 4 ml of media to it
to neutralize the activity of trypsin EDTA solution) and spin down in the centrifuge (5 min at 1000 rpm) in
a 15 ml conical tube. The supernatant was decanted, and the cell pellet was broken down gently by agitating
the conical tube. Cells were resuspended in 1 ml of media and transferred into small 0.5 ml or 1 ml
centrifuge vial and spin down again. After decanting the supernatant media Geltrex (GIBCO, LDEV-Free,
hESC-Qualified, Reduced Growth Factor Basement Membrane Matrix) was added such that the total
concentration of cells is around 106-107 cells/ml. Geltrex mixed cells were introduced into the cell chamber
and sealed with glass. The device setup was completed by filling media reservoirs with appropriate culture
media and transferring the whole setup into the incubator.
Media component’s (U2OS media)

For 100 ml

McCoy's 5a Modified Medium

90 ml

(Catalog No. 30-2007)
Fetal bovine serum (FBS), ESCqualified (16141079)

10 ml

Table 1: Media composition of U2OS media.

2.2.4 Anti-cancer drug assay
Methotrexate (Cayman chemicals: 13960), Cisplatin (Cayman chemicals: 13119), and Doxorubicin
(Cayman chemicals:15007) are the commonly used anti-cancer drugs. Stock samples of these drugs were
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prepared in DMSO as per the manufacturer data sheets. Concentration gradient of the drug was generated
in the microdevice by supplying the drug mixed culture media in one channel while the other channel
without drug, thereby creating a source and sink model and establishing a linear drug gradient across the
cell chamber.
2.2.5 mESC cell culture
Embryonic stem (ES) cells with ALS phenotype mutations in the TARDBP gene and a Hb9::GFP
reporter were derived from crossing B6.Cg-Tg (Prnp-TARDBP*A315T) 95Balo/J mice with B6.Cg-Tg
(Hlxb9-GFP)1Tmj/J mice (The Jackson Laboratory, Bar Harbor, ME, USA (JAX)). Enhanced GFP (green
fluorescence protein) is expressed under the control of the mouse Hb9 promoter, and thus, eGFP expression
can be used to identify putative motor neurons135. Motor neurons (MNs) differentiated from this cell were
called Mutant MN. Embryonic stem cells with Hb9::GFP as a reporter gene and without any mutant gene
for ALS (referred as Control mESC) were differentiated to MNs (referred as Control MN). Both the cell
lines were donated by Dr.Greg Cox Lab (The Jackson's laboratory).
Growth & Propagation of mESC (Maintenance): Mytomyicn-c (myc) (sc-3514B) treated mouse
embryonic fibroblasts (MEF) dishes were prepared 2 days ahead of mESC culture. Untreated MEF were
cultured to 80 % confluency on a 60 mm dish in MEF media (Table 2). Then regular MEF media in the
dish was replaced with myc-mixed MEF media at 10 µg/ml mitomycin concentration and cultured for 2-3
hr in the incubator. The myc-media was decanted and the dish (with cells) was washed twice with PBS to
get rid of any leftover myc. Finally, MEF media was added to the dish and left for a day or two before
adding mESC.
A vial of mESC retrieved from liquid nitrogen tank was thawed and added to the 60 mm dish,
which has mitomycin-c treated mouse embryonic fibroblast (MEF) plated on them. Cells were cultured on
the feeder cells (MEFs) for 2-3 days for growth and propagation in mESC media (Table 2) before the device
experiment.
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Table 2: Composition of mESC growth/maintenance media & MEF maintenance/growth media
Media component’s (mESC media)

For 100 ml

Knockout DMEM/F-12 (12660012)

82

DMEM-high glucose (11965092)

89

Knock Out Serum Replacement
(KOSR) (10828028)

15

Fetal bovine serum (FBS), ESCqualified (16141079)

10

Non-Essential Amino Acids (NEAA)
(11140050)

1

MEM-Non-Essential Amino
Acids (NEAA) (11140050)

1

GlutaMAX (35050061)

1

(L-alanyl-L-glutamine dipeptide)

Media component’s (MEF
media)

2-mercaptoethanol,55 mM
(21985023)

Antibiotic-Antimycotic (sc3690)

1

mouse LIF recombinant protein
(10ug/ml) (PMC9484)

100 µl

2-mercaptoethanol,55 mM (21985023)

100 µl

For 100 ml

100 µl

2.2.6 3D differentiation of mESC to motor neuron in the microdevice
On the day of the microdevice experiment, mESC were trypsinized (using 0.5-1 ml of 0.25%
trypsin- 0.03% EDTA solution) for 4 mins in an incubator and 4 ml of media (with serum) was added to it
to neutralize the activity of trypsin EDTA solution. Detached cells were spin down in the centrifuge (5 min
at 1000 rpm) in a 15 ml conical tube. Two gravity separation (1 hour each) was carried out to isolate the
mESC from the feeder cells. (for gravity separations, cells are replated on gelatin coated dishes)
Relatively pure embryonic stem cells (Control or Mutant) were suspended in GeltrexÔ (GIBCO,
LDEV-Free, hESC-Qualified, Reduced Growth Factor Basement Membrane Matrix) at 40C at a density of
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106-107 cells/ml. 0.3 µl of cell-ladened gel matrix was dispensed into the microfluidic device culture
chamber and allowed to polymerize by warming to 370C. Because of the small sample volume, both gel
matrix cooling and heating could be performed within several seconds, minimizing stress to the ES cells.
Fluidic connections to the microdevice were immediately made to establish continuous perfusion
to the embryonic stem cells with an appropriate media (MN differentiation media (ADFNK media)
with/without rapamycin). MN differentiation factors (3µM PM and 1µM RA) were supplied along with
ADFNK media for 7 DIV.
Media component’s (ADFNK media)

For 50 ml

Advanced DMEM/F-12 (12634010)

22 ml

Neurobasal (21103049)

22 ml

Knock Out Serum Replacement (KOSR)
(10828028)

5 mL

Antibiotic-Antimycotic (sc3690)

50 µl

GlutaMAX (35050061)
(L-alanyl-L-glutamine dipeptide)

0.5 ml

2-mercaptoethanol,55 mM (21985023)

50 µl

Retinoic acid (RA) (stock: 10 mM)
(11017)

5 µl
(1uM)

Purmorphamine (PM) (stock :10 mM)
(1009634)

15 µl
(3uM)

Rapamycin (10 mM)

10 µl
(2 µM)

Table 3: Composition of mESC to motor neuron differentiation media (referred as ADFNK media)

2.2.7 Rapamycin treatment
Rapamycin diffusion gradient was established across the cell culture chamber by addressing one
microfluidic channel with MN differentiation media containing 2µM rapamycin while addressing the
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second microchannel with only MN differentiation media (0 µM rapamycin). The flow rate in each channel
was kept constant at ~100 µl/hr for the duration of the experiments. This maintained a linear rapamycin
gradient across the MN culture with 2 µM rapamycin at the high end and 0 µM rapamycin at the low end,
thereby exposing MN cultures to a range of rapamycin concentrations in a single device. The precise
concentration that each MN experiences was a function of its spatial position within the microdevice
chamber.
2.2.8 Device preparation and sterilization
Prior to starting cell culture in the microdevice, all the components of the device that come in
contact with culture media or cells need to be sterilized properly to avoid any contamination. Sterilization
was carried out by rinsing and drying (30 min) with 70% ethanol followed by multiple rinses with
autoclaved and filtered (0.45 µm) DI water to remove any leftover ethanol. Before proceeding for
sterilization, a small amount of uncured PDMS was applied 500 µm away from the top and bottom (vias
side) edges of the chambers which acts as a greasy barrier between coverslip and device. After the
sterilization, device is left to dry inside the sterile hood with 30 min of UV treatment to the top and bottom
side of the device for improved sterilization. Channels were vacuumed out for any leftover water droplets
before the start of the experiment to keep them completely dry. Coverslips (~160 µm thick) used for sealing
the cell culture chamber are diced into appropriate size using a standard wafer dicing saw that can cover
the chamber (4 x 2 mm). Coverslips are also sterilized by soaking them in 70% ethanol and then rinsed in
DI water for 10 mins respectively, followed by 10 min of UV treatment in the hood. For ease of
experimentation and better time management while loading the device with cells, the sterilized coverslips
are arranged such that they are easy to access/handle with tweezers.
2.2.9 Immunocytochemistry
For staining the cultured samples in the device, coverslips covering the chambers were removed
and the device was processed accordingly for the staining (detailed process flow of immunostaining can be
seen in Figure 13).

17

2.2.9.1 Live-dead staining of cells
Devices with exposed chambers (coverslips removed) were incubated (at 37oC for 15-30 mins)
with U2OS media containing Hoechst-33342 trichloride trihydrate (10 mg/ml: H3570) at 1:500 dilution
and Propidium Iodide (1 mg/ml: P3566) at 1:1000 dilution for differentiating live cells from dead cells.
Images were captured using Zeiss Observer Z1 inverted microscope.
2.2.9.2 Motor neuron immunostaining
Following 7, 14, 21 days in vitro (DIV), ES cell-derived motor neuron cultures were fixed using
4% paraformaldehyde in PBS for 10 minutes followed by several washes in PBS and incubated with
antibodies against TDP43 (1:500; ProteinTech), GFP (1:500; Aves Biologicals) in PBS containing 10%
goat serum at 4o C overnight. The cells were subsequently washed with PBS, incubated with Alex Fluor
488, 555, 637 secondary antibodies (1:500; Invitrogen) at room temperature (RT) for 2 hrs. Stained samples
were imaged using Zeiss Observer Z1 inverted microscope at different magnification.
2.2.10 Image analysis and quantification
For image analysis and quantification, the cell chamber was virtually divided (ImageJ: region of
interest-ROI) vertically into ten 100 µm zones (permissive zones or bins) along the gradient. Each zone
represents a region of approximated rapamycin/anti-cancer drug concentration based on a linear
concentration profile.
In case of anti-cancer drug assay, the nuclear stain of Hoechst-33342 to propidium iodide are
counted to calculate the cell viability across different concentrations.
For rapamycin assay, fluorescence intensity corresponding to the number of positive cells (in our
case motor neurons) was plotted against the rapamycin concentration. A native eGFP response on DIV-7
(day-7) was used as the baseline for GFP intensity expression. Two-way ANOVA in conjunction with an
appropriate multiple comparison test was performed for statistical significance.
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2.3 Results
2.3.1 Micro device fabrication
Gradient generating microdevice used for microengineering neural tube by Dr.Demers (SmithCollins group) was utilized in current drug assay study. An overall process flow of the fabrication of the
microdevice is attached in Figure 3. A brief overview of the fabrication process is discussed here. RCA
cleaned double-side polished silicon wafers were used in the fabrication of the device. Steam oxidation at
1100 0C for approximately 1.5 to 2 hr was carried out on the wafers to generate around 500 nm SiO2.
Photoresist (AZ1512) was deposited on both sides of the wafer and chamber (cell culture chamber, Figure
4c) mask was patterned and developed. BOE (buffer oxide etchant) was performed to etch the exposed
oxide. Photoresist was stripped off and a new layer of photoresist (AZ1512) was added to the wafer and
“via mask” (via’s are small openings through which media diffuses, Figure 4c) was patterned, exposed and
developed. Deep reactive ion etching (DRIE) was performed to etch around 20 µm on the wafer. This was
followed by photoresist strip and another round of DRIE, to etch the chambers (100 µm) on the backside
of the wafer. The oxide on the front side of the wafer was always protected from BOE by a coating of
photoresist. Wafer with cell chamber and vias etched on the backside is processed for front side by flipping
the wafer and aligning the existing design on the backside to the new mask for the high resistant channel
on the front side. This was carried out by coating with a thin layer (2 µm) of photoresist (AZ1512) coupled
with BOE to etch the oxide and generate patterns of high resistance channels. The photoresist was stripped
off, thick photoresist (SPR220) was applied on the front side, and deep channels mask was patterned,
developed and followed by DRIE to etch around 375 µm of exposed silicon pattern. Thick resist was
stripped off and high resistance channels were etched (oxide acts as a mask). The “vias” opened up by the
end of this etch and the any remaining oxide was etched in BOE. The device was anodically bonded to
pyrex glass (with drilled holes aligning to the high resistant channels). Media reservoirs (diced cryotubes)
and outlets (silicone tubing) are attached to the device using Factor-II silicone glue. Appendix-B lists the
microfabrication process and detailed parameters.
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Figure 3: Microfabrication process flow of gradient generating microdevice.
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2.3.2 Characterization of the microdevice
A full explanation outlining the generation of 3D concentration gradients was presented in
Demers.et.al99,127. A steady-state concentration gradient concentration profile across a cell culture was
generated using a source and sink model. Rapamycin/anticancer drug was introduced to one side of the cell
chamber at a high constant concentration (source) and allowed to freely diffuse to a lower concentration
(sink) on the opposite side of the microdevice cell chamber (Figure 4c). This results in a linear rapamycin
concentration across the microdevice cell chamber from source to sink. The spatial gradient of
rapamycin/anticancer drug was used to identify the viability of ALS exhibiting motor neurons, where each
position (bin) across the chamber represents a specific concentration of rapamycin.
COMSOL Multiphysics, a finite element analysis program was used to model rapamycin
concentration gradient across the cell chamber (Figure 4a). The modelled data was compared with the
experimental data. Experimental data was obtained by establishing linear fluorescein concentration gradient
across the gel filled chamber of the microdevice and quantifying the fluorescent profile by measuring the
fluorescent intensity at 520 nm (excitation 488 nm) as a function of distance across the chamber (Figure
4b). At short diffusion times, profiles followed normal error function transitioned into a linear steady-state
gradient in about 10-20 minutes. The linear profiles were stable as long as the fluorescein concentrations at
the two boundaries (source and sink) were continually refreshed with reagent flow from the microchannels,
i.e., boundary concentrations kept constant (Figure 4d).
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Figure 4: Validation of diffusion profiles in the microdevice.
a) COMSOL simulations of a developing fluorescein diffusion profile as a function of time. Initial diffusion
profiles follow the general Cottrell equation, but quickly transition into a linear, steady-state profile with
time. Intensities are normalized to 1.0 for a source fluorescein concentration and 0 for the sink fluorescein
concentration. Inset, middle, shows the source/sink configuration with the diffusion profiles using a
diffusion coefficient of 4.9 × 10−6 cm2 s−1 for fluorescein. c) A cross-sectional view of the microdevice
illustrating the various features of the device cell culture media flows through the “channels” and diffuses
through the “Vias” into the “Cell chamber”. b). Experimentally measured diffusion profiles using the
optical emission of fluorescein at 520 nm. Micrographs to the right show a developing diffusion profile
across the microdevice chamber (1 mm x 1 mm) at various times. A uniform linear diffusion gradient is
clearly evident post 30 min of diffusion and remains linear for as long as the source and sink concentrations
are maintained in this case 24 hrs before the experiment was terminated.
Computational modeling parameters were as follows: Flow rate 100 µl/hr, diffusion coefficient (D) of 4.9
× 10−6 cm2 s−1, Temperature: 293 K, Arbitrary source concentration (1 µM) and sink (0 µM).

22

2.3.3 Microsystem for drug assay: Identifying dosage dependency of anti-cancer drugs in treating
osteosarcoma (U2OS cells)
U2OS cells were 3D cultured in the microdevice by mixing them with geltrex (basement
membrane). Cells mixed with geltrex at 1 x 107 cells/ml seeding density were loaded into the microdevice
and covered with a glass coverslip. Drug mixed U2OS media (Table 1) was introduced in one channel,
whereas media without any drug in the opposite channels, thereby creating a drug gradient across the cell
chamber as explained in the above section (3.2). The gradient in the chamber was maintained as long as
source and sink conditions are maintained. Flow rate was maintained at 100 µl/hr. Three different
commonly used anti-osteosarcoma drugs, doxorubicin (80 µm), methotrexate (80 µm), cisplatin (100 µm),
were assayed to identify the concentration dependent cell mortality. Cells were cultured under a drug
gradient for two days and stained for lived dead analysis. Figure 5 represents the observed gradient assay
for the three drugs. Hoechst-33342 (stains DNA of all cells) and propidium iodide (stains DNA of dead
cells) were used to identify the cell viability in the microdevice. As observed from Figure 5 (a,c,e), at a high
concentration of the drug, an increased amount of dead cells (more red/magenta) were observed and as
moved down across to the other side of the chamber concentration decreases and in turn number of dead
cells (stained red for propidium iodide) also decreases. To quantify the cell viability across the chamber,
the cell chamber was divided into bins of 1000 x 100 µm (w x h) and stained cells (nucleus) were counted
using ImageJ. The bin position gives an approximation of the concentration in that region of the cell
chamber. Cells stained positive for propidium iodide count for dead cells and live cells can be counted by
subtracting dead cells from total cells (stained positive for Hoechst-3342). All the data was normalized to
the total no. of cells in each bin and plotted against different concentrations each drug. As the sample size
n=1, standard deviation and statistical analysis were not carried out because of the absence of reproducible
data.
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Figure 5: Anti-cancer drug assay in the microdevice.
The arrows represent media flow in the device. The gradient profile next to the image represents the high
to low concentration gradient of the drug. Sample size n=1 a) Stained (Hoechst and Propidium iodide) cells
in doxorubicin treated microdevice with high (60 µm) to low (0 µm) concentration b) quantification of the
doxorubicin assay across different concentration regions in the microdevice c) Live dead stained
methotrexate treated microdevice with high (60 µm) to low (0 µm) concentration in a microdevice and d)
quantified methotrexate assay data across different concentration. e) Live dead stained cisplatin-treated
microdevice with high (100 µm) to low (0 µm) concentration in a microdevice f) represent the quantified
cisplatin assay at various concentration.

Quantified assay results from Figure 5 (b, d & f) represent the cell mortality and the concentration
of the drug needed to arrest the propagating of osteosarcoma (U2OS) cells. LD50 values of the anti-cancer
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drugs in a 3D culture from literature are similar to those observed approximated values from a single device
experiment, e.g...doxorubicin136 (~18 µM), methotrexate137 (~ 42 µM), cisplatin137 (~ 30 µM).The above
results indicate and highlights the ability to perform a whole assay in a single device. Apart from this, the
device also simulates a similar in vivo environment and drug treatment conditions, i.e., dense cancerous
tissue with high drug concentration being exposed to the outer layer compared to inner tissue mass. Thereby
this platform also provides us an opportunity to understand dosage-dependent intercellular communication.

Figure 6: Challenges in reproducing the drug assay in the microdevice.
This figure provides methotrexate assay as an example at different concentration and culture conditions
(2D and 3D). Sample size n=3 a) Hoechst and PI staining for live/dead cell after 48 hr treatment with
methotrexate (200 µm) and b) corresponding quantification representing sporadic cell mortality without
any correlation to assay profile c) Hoechst and PI staining for device cultured under a gradient of
methotrexate (100 µM to 0 µM) (a squared device chamber, different from the previous hexagonal design)
d) quantification of the methotrexate assay (100 µM to 0 µM concentration) in the microdevice represent
dead cells all over the chamber. e,f) an example of cell cultured in 24-well plate and exposed to a high
concentration of drug (methotrexate 100 µM) and the quantified data which does not correlate with the
microdevice assay (c,d).
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With above assay result, the device-based drug assay was repeated for reproducibility and better
quantification of the cell viability at different concentrations across the device with a high sample number
(n ≥3). But unfortunately, the assay was non-reproducible, thereby questioning the authenticity of drugmediated mortality (Figure 5). Different concentrations of the drugs ranging from 20 - 200 µm were tried
to reproduce the assay profile as observed in Figure 3. Figure 6 is an example which represents the
inconsistency in cell viability at different concentrations of methotrexate. At higher concentrations of
methotrexate 200 µM (Figure 6a, b), the overall mortality (number of dead cell) was lower than the lower
concentration (100 µM) (Figure 6c,d). Every retry with other two drugs resulted in similar results i.e., either
complete dead cells (Figure 5d) or sporadic dead (Figure 6b) cells without any correlation to the drug
gradient profile (Figure 5a,c) across the chamber. The cause for this erratic and non-reproducible results
were not clear. As a control, cells were cultured in a 24 well plate and exposed to a high concentration of
drug (100 µM of methotrexate similar to Figure 6c,d) to observe for the expected high mortality of U2OS.
Contradicting the expectation a high mortality rate was not observed in control (Figure 6e,f). Similar results
as Figure 6 were observed when the assay was retried with other two drugs (cisplatin and doxorubicin)
without any reproducibility (sample to sample) in a single experiment itself. One of the possible causes at
least in the case of cisplatin was the usage of DMSO as a carrier agent. It was noted from Hall138 et.al. that
platinum-based compounds in the presence of DMSO undergo ligand displacement and changes in the
structure of the complex, thereby decreasing the ability of the drug to kill cancerous cells. This
supplemented with complex 3D culture might be the cause for failure of cisplatin assay in the microdevice,
whereas the reasons for the inability of the other two drugs in arresting/killing U2OS is still unclear.

2.3.4 Microsystem for disease modeling: Rescue of MN with ALS phenotype using rapamycin
Current approaches of ALS pathology involve in delaying the progression of disease139 but more
emphasis should be on preventing/clearing unwanted protein140 aggregates which is an hallmark of ALS
pathology .The unwanted protein aggregated of TDP-43 were localized to the cytoplasm and clearing them
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using an mTOR inhibitor like rapamycin is promising89 approach. In the following sections, efficacy of
rapamycin to salvage ALS phenotypes was investigated in 3D and a 2D cultures.
2.3.4.1 Rapamycin assay in 2D culture
A detailed study of effect of rapamycin in rescuing the degenerating ALS motor neurons was
carried out by Chennampally141 et.al. in collaboration with Dr. Greg Cox's lab. This current section of the
data was carried out at the Jackson lab and presented here for ease of understanding and also to provide a
preface for the 3D assay of rapamycin in a microfluidic device. Both control and mutant ES cells were fully
differentiated into MNs for 7 Days in vitro (DIV) using standard MN differentiation media (Table 3), the
cultures were then exposed to 1µM rapamycin and MN viability was monitored at 14 DIV, 21 DIV and 28
DIV. By 28 DIV rapamycin treated mutant cells in comparison to the untreated mutants showed a 54.91±5.6
% increased MN survivability (p ≤0.001 & n ≥ 3 by two-way ANOVA-sidak test). Absence of cytosolic
ubiquitinated TDP-43 aggregates (Figure 7b) in 1 µM rapamycin treated mutant samples compared to that
of presence in case of untreated mutant samples indicate the effectiveness of rapamycin in rescuing ALS
phenotypic MNs.

Figure 7: Rapamycin assay in 2D culture.
a) Mutant (A315T) MNs show an increase in survival when treated with 1µM of rapamycin with %GFP+
cells equivalent to those of control at 21DIV and 28DIV. Mutant MNs not treated with rapamycin show a
rapid decrease in survival from 7DIV to 28DIV compared to the control MNs(Untreated Control). All
fluorescent intensities were normalized to 100% at 7 DIV. b) Immunostaining of treated and untreated
mutant MNs for cytosolic TDP-43 and Ubiquitin showing the reduction/absence of the cytosolic aggregates
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in the treated samples compared to that of untreated samples (arrows are indicating the cytosolic
aggregates). P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

2.3.4.2 Rapamycin assay in 3D microdevice
The above experiments demonstrated potential use of rapamycin to rescue the ALS MN
phenotypes. With an increased emphasis on using 3D culture over 2D culture especially in cancer biology
and drug discovery142 adapting the rapamycin treatment in ameliorating ALS phenotype in a 3D culture
was essential. 2D culture is well studied and robust but it does not represent the in vivo environment
correctly. The 3D cell culture generally preserve the inherent morphological and phenotypical cell
development more faithfully. Here a microfluidic device capable of generating rapamycin concentration
gradients within a 3D gel matrix was explored to identify the growth zones for the ALS phenotype as a
function of the spatial rapamycin concentration. This 3D microfluidic gradient generating platforms not
only provides an in vivo like environment for drug testing, but also has a high throughput rate. Though
microfluidic platform offers many advantages it has its own limitation such as inability to obtain high
resolution images of the subcellular structures. This can be attributed to absorption and light scattering of
the thick extracellular matrix in which MNs grow as a cluster. So to visualize the sub-cellular components,
samples from 2D cell culture were used.
ES cells, both control and mutant were differentiated into MNs for 7 DIV in the microdevice using
standard MN differentiation media according to protocols outlined in the methods section. A MN cell
identity was confirmed by expression of the Hb9::GFP reporter (eGFP). At 7 DIV, the MNs were then
exposed to a linear rapamycin gradient for the remaining duration of the experiment by introducing 2 µM
rapamycin into the source media and 0 µM rapamycin in the sink media. Immunostaining of MNs was
carried out using anti-GFP and anti-TDP-43 antibodies at 14 DIV and 21 DIV (Figure 8a &Figure 9a). GFP
was used as a marker for differentiated motor neurons and anti-TDP-43 was used to stain TDP-43
aggregates. GFP+ fluorescent intensities were plotted as a function of rapamycin concentration, i.e., the
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spatial position in the microdevice. Intensities were averaged over five samples and normalized to eGFP
fluorescent intensities at 7DIV, i.e. all average eGFP intensities at 7DIV were normalized to 100%.

Figure 8: Rapamycin assay in microdevice (14DIV).
a) Typical microdevice immunostaining for GFP and TDP-43 at 14DIV under a rapamycin gradient. Red
sidebars immediately to the right indicate the spatial direction of the rapamycin gradient (red: 0µM - 2µM)
while the blue bars indicate a constant concentration of culture media morphogens. b) Plots the average (n
≥ 4) percent viability of rapamycin treated MNs (GFP+) i.e. viability of treated mutant MNs (red) and
treated control MNs (green) as a function of rapamycin concentration. *Indicates both mutant and control
MNs which are not exposed to rapamycin, i.e. untreated MNs respectively. c) Shows the relative MN
toxicity of rapamycin on control MNs, i.e. the percent viability of rapamycin treated control MNs minus
the average viability of rapamycin untreated control MNs. A positive (+) value indicates an increased
survival of control MN’s without rapamycin and a negative (-) value indicates a toxicity effect of
rapamycin. P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

By 14 DIV the untreated mutant MNs demonstrated a 24.4±13 % (p≤0.001, n≥ 4, two-way
ANOVA-sidak test) lower viability than their untreated control MNs as indicated in Figure 8b, 0 µM
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rapamycin. Again, a general loss of untreated MN viability with time is expected and attributed to normal
cell losses during early MN development and growth. It is encouraging that at 14 DIV rapamycin treated
mutant cells showed virtually complete rescue over all rapamycin concentrations when compared to the
corresponding treated control MNs (Figure 8b). This is also consistent with the absence of TDP-43
cytoplasmic aggregates in rapamycin treated 2D MN cultures (Figure 7b). However, a general MN toxicity
begins to emerge which is shown clearly in Figure 8c. Here the relative percentage of viable control MNs
as a function of rapamycin concentration is plotted for 14 DIV using the concentration of untreated control
(0 µM rapamycin) as a reference, i.e. percent viability for rapamycin treated control MNs minus untreated
control MNs. Generally, little to no rapamycin sensitivity is seen at low rapamycin concentration for shorter
exposure times (<14 DIV), but for rapamycin concentrations >1 µM, a small but noticeable decrease in MN
viability begins to emerge (e.g., comparing MN viability at 0.4 µM to 1.8 µM in figure 6c, a 21.47±14 %
decrease in MN viability is observed, with a p ≤0.01 & n≥ 4 by a two-way ANOVA-sidak test) and becomes
more pronounced at longer rapamycin exposure times, see 21 DIV (Figure 9c).
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Figure 9: Rapamycin assay in microdevice (21DIV).
a) Typical microdevice immunostaining for GFP and TDP-43 at 21 DIV under a rapamycin gradient. Red
sidebars immediately to the right indicate the spatial direction of the rapamycin gradient (red: 0µM-2µM),
while the blue bars indicate a constant concentration of culture media morphogens. b) Plots the average (n
≥ 4) percent viability of rapamycin treated MNs (GFP+) i.e. viability of treated mutant MNs (red) and
treated control MNs (green) as a function of rapamycin concentration. *Indicates both mutant and control
MNs which are not exposed to rapamycin, i.e. untreated MNs respectively. c) Shows the relative MN
toxicity of rapamycin on control MNs, i.e. The percent viability of rapamycin treated control MNs minus
the average viability of rapamycin untreated control MNs. A positive (+) value indicates an increased
survival of control MN’s without rapamycin and a negative (-) value indicates a toxicity effect of
rapamycin. P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

As cells progressed to 21 DIV, it was not surprising to see a 42±10 % (p ≤ 0.001, n≥ 4, two-way
ANOVA-sidak test) increase in mortality for untreated mutant MNs compared to the untreated control MNs
(Figure 9b, 0 µM rapamycin). However, several interesting trends also surfaced. First, low rapamycin
concentrations (≤ 0.2 µM) were ineffectual in salvaging mutant MNs, most likely due to reduced inhibition
of the mTOR pathways and/or suppressed TDP-43 clearing, resulting in significant TDP-43 cytoplasmic
depositions. This is not surprising as most therapeutic drugs have threshold concentration limits, both high
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and low. Second, rapamycin concentrations between 0.4 to 1.0 µM presented a permissive MN growth zone
for both control and mutant MNs. Over this region rapamycin treated mutant MNs showed a dramatical
increase in viability, 40.44±11 % (p ≤ 0.001, n ≥ 4, two-way ANOVA-sidak test) in comparison to untreated
mutant MNs (Figure 9b, 0 µM rapamycin), while control cells demonstrated little to no adverse effects from
rapamycin exposure. Third, at high rapamycin concentrations >1.4µM, control MNs experienced a
substantial decrease in MN viability (e.g., comparing MN viability at 0.4 µM to 2.0 µM in Figure 7c, a
26.1±13 % decrease in MN viability is observed, with a p ≤ 0.001 & n≥ 4 by a two-way ANOVA-sidak
test), indicating increased toxicity from 14 DIV to 21 DIV (Figure 7c, compared with Figure 6c, Sheet S1
for two-way ANOVA group comparisons), and while rapamycin treatment still salvaged mutant MNs from
demonstrating the ALS phenotype, mutant MNs also showed a steady loss of viability at higher rapamycin
concentrations (Figure 9b, compare with Figure 8b).
Nevertheless, an increase in the TDP-43 aggregates per MN at different time interval with an
observed increase in untreated MN mortality from 2D (Figure 7a) and 3D (Figure 8a &Figure 9a) MN
cultures indicate a possibility that the cytosolic TDP-43 aggregates are related to the increased mortality in
mutant MNs and rapamycin was able to rescue these mutant MNs from degeneration in both 2D and 3D
cultures indicating a potential path for ALS remediation.
2.3.5 Challenges in MN differentiation in microdevice
MN differentiation in microdevices was sensitive to various parameters. For example, maintenance
of mESC cultures before differentiation experiment in the microdevice should result in colonies of the
mESC as shown in Figure 10a for successful differentiation of mESC to MNs. If mESC colonies are not
formed (Figure 10b) the following differentiation of mESC to MN will result in no GFP positive cells (no
MN). Non-formation of mESC colonies was usually due to less starting seeding density (either feeder cells
or mESC). The other possibility was due to usage of expired mESC media (or media components). One of
the other significant challenges in differentiating MNs in a microdevice was a high cell seeding density
(more than 4 x 107) which results in bands of MNs (top and bottom of the chamber) with no eGFP
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expressing cells in the center of the cell chamber. When this device was stained for Hoechst and propidium
diode (Figure 10d), it clearly depicts band of dead cells in the center of the chamber. This can be attributed
to nutrient deprivation to the cells in the center of the chamber resulting in cell death.

Figure 10: Challenges in MN differentiation.
a) an example of good mESC colonies in maintenance media for successful differentiation compared to b)
non-formation of colonies results in no MN differentiation. The reason for the absence of colony formation
can be attributed to expired maintenance media/components or insufficient seeding density. c & d) eGFP
and Hoechst-33342 and PI staining for live dead staining representing a band of dead cells in the center of
the device. This is due to high cell loading density or interrupted or inadequate/stopped media flow.
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2.4 Conclusions
The designed device was successfully characterized for the concentration gradient generation using
the finite element model and fluorescent dye study. The fabricated microfluidic gradient generator was used
to culture osteosarcoma cells in 3D and perform a drug assay for dosage-dependent study to restrict cancer
proliferation. Initial results indicated the dosage dependent effect of anti-osteosarcoma drugs (doxorubicin,
cisplatin, methotrexate), but this data was not reproducible. Reason for non-reproducibility in case of
cisplatin was carrier reagent (DMSO) affecting the conformation of the drug and thereby decreasing the
activity. It is still not clear why the other two drug assays were not reproducible. Yet this study highlights
the ability of the platform to perform a drug titration in a single device elucidating its capability for high
throughput analysis.
Though the cancer drug assay was not fruitful, this microfluidic gradient generator was used to
successfully understand the effect of rapamycin on MNs exhibiting ALS phenotype. Using the microfluidic
platform, we demonstrated an optimal 40.44% rescue of the ALS phenotype over a concentration range of
0.4 – 1.0 µM. The drug was ineffectual in rescuing the ALS phenotype for lower rapamycin concentrations,
while rapamycin demonstrated significant toxicity for higher concentrations and exposure times. This
strongly suggests potential remediation of ALS is possible using mTOR inhibitors such as rapamycin. As
mentioned before, an essential advantage to the microfluidic assay presented here is that an entire rapamycin
titration was performed in a single cell culture experiment (with replicates), thereby greatly enhancing test
throughputs and results. Furthermore, the small size of the device, 1mm x 1mm, allows for parallel testing
of large device arrays, increasing the testing throughput, thereby enabling drug discovery and screening, as
well as patient-specific drug screening and treatment. Due to the intrinsic potential of the microfluidic
device to differentiate cells in 3D and retain their spatial and morphological construct similar to in vivo, in
the future a modified design of this current platform can be utilized in exploring and understanding axonal
progression and degeneration over time in ALS cell lines (mESCs and human IPSCs) while performing a
therapeutic screening/treatment.
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CHAPTER 3 : DEVELOPMENTAL STUDY IN A COCULTURE DEVICE: SUBTYPE
SPECIFIC DIFFERENTIATION OF MOTOR NEURONS IN PRESENCE OF SKELETAL
MUSCLES
3.1 Introduction
Motor neurons (MNs) are generated in the ventral region of the developing neural tube under
chemical gradients of morphogens like Retinoic acid (RA), Sonic hedgehog (Shh), Bone morphogenic
protein (BMP), etc. These morphogens induce expression of transcription factors distinctively, thereby
generating domains of cell type specific regions along the dorsoventral (DV) axis of a neural tube143.
Including MNs, there are 11 different types of neurons differentiated under the influence of morphogens
across the dorsoventral axis. The Shh concentration gradient from the notochord at different time intervals
plays a significant role in establishing ventral cell types144 . At the same time, opposing gradients of BMP
and Wnt (Figure 11b) from the roof plate are involved in the dorsal cell type determination145.
Across the three regions of the developing spinal cord/neural tube (brachial, thoracic and lumbar),
expression of different Hox genes divides the MNs along the anterior-posterior (AP) axis into different
columns (median motor column: MMC, hypaxial motor column: HMC, lateral motor column: LMC,
preganglionic motor column: PGC)146. These motor column MNs are further classified into motor pools
based on the specific muscle targets. Expression of different Hox genes across the anterior-posterior axis is
governed by the concentration gradient of RA in the anterior region and fibroblast growth factor (FGF) and
growth differentiation factor (GDF11) in the posterior region147 (Figure 11a). Hensen’s node and presomatic mesoderm are the primary source of FGF and GDF11 in the caudal region, whereas RA signaling
is provided by the paraxial mesoderm and somites147(round spherical tissues flanking the neural tube during
embryonic development148). Due to the transient nature of the morphogen signal, Hox genes have
established a combinatorial code in which an anterior-posterior identity is determined by co-expression of
a specific protein103,149. Hox gene expression is not only involved in MN differentiation and positioning but
also governs muscle patterning and differentiation150,151. Skeletal muscle, dermis, cartilage, etc., are
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developed from somites (paraxial mesodermal structures) during embryonic development. In a dorsoventral
axis, opposing gradients of BMP, Wnt from the roof plate/ectoderm and Shh, noggin from the floor
plate/neural tube differentiate the somites into skeletal muscle, vertebra and cartilage across the developing
neural tube. This indicates an overlapping and complex system of patterning between muscle and motor
neurons under the influence of morphogen and Hox gene patterning.
Factors effecting the generation of motor neuron subtypes in vitro and in vivo has been researched
extensively152,153. Among the subtypes of MNs, generation of LMC motor neurons in vitro is challenging.
MNs of this column are explicitly involved in innervating the limb skeletal muscle and first to die in case
of neurodegenerative diseases like ALS. Different approaches such as overexpression of a specific
transgenic factor154 or exposing the differentiating cells to signaling factors135,155 has been explored for
LMC generation in vitro. However, these approaches are proven to be tedious and low yielding when
modelling for a disease or in the development of precision medicine. Furthermore, most of these in vitro
studies are performed in a culture dish that does not truly represent the in vivo spatial organization, thereby
limiting the scientists in exploring the complex biochemical pathways. Thus, there is a need for a system
which can culture different cell types separately but still capable of intercellular communication to truly
represent a disease model or developmental process. Microfluidic coculture systems were promising in
addressing these challenges. Various coculturing system has been used in myriad areas of biology in
exploring cell-to-cell interaction during development (neuroglia with CNS organoid156, astrocytes and
neurons157, retinal pigment epithelium, and neural retina158, etc.)159 and/or the effect of drugs on various
tissues in conjunction160.
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Figure 11: Anterior-posterior patterning under morphogen gradient
a) anterior-posterior patterning of MN into different columnar identity. A gradient of FGF, Wnt, and GDF
is present in the posterior region of the neural tube, whereas an opposing gradient of RA is in the anterior
region. b) cross-section of neural tube with concentration gradients across the dorsoventral axis, generating
dorsal interneuron (dI1-6), ventral neurons (V0-3) and motor neurons at different regions. c) representation
of in vitro cell culture device to study the effect of skeletal muscle/somites in generation MN. LMC (lateral
motor column), MMC (median motor column), HMC (hypaxial motor column), PGC (preganglionic motor
column). (source for the gradient generation images 107,108).

To understand and explore the complex overlapping neuro muscular development, we designed a
gradient generating microfluidic system capable of culturing two different cells/tissue in a 3D
microenvironment with connecting channels to enable cell communication (Figure 11c). This is a first
report of using an adjacent coculture system to study the effect of skeletal muscle on differentiating MNs.
Disease modelling and drug dosage dependent studies can also be carried out in the current coculture device.
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3.2 Materials and methods
3.2.1 Cell culture
A majority of the procedure in this current research involves cell culture and associated processes.
Cell culture involves primary culture and subculture of cells. Primary cultures of cells can be defined as
cells that are obtained directly from tissues/animals. Subculture (passaging) of cells involves taking a part
of the primary culture and expanding them for further experimentation. A typical procedure of passaging
cells involves retrieving and thawing a vial of cells from the liquid nitrogen/freezer. This was followed by
mixing thawed cells with fresh media (4 ml) and centrifuging (1000 rpm for 5 mins) the mixture to separate
the freezing media from cells. After centrifugation, the liquid mixture was decanted carefully without
disturbing the cell pellet on the bottom. The cell pellet was loosened by gently dragging the centrifuge tube
across the hood grill for gentle mechanical agitation and easy dispersion in the media. The separated cells
were mixed with fresh media and transferred to a dish for proliferation. The most common process followed
after subculturing and before the start of the experiment or another subculture is trypsinization.
Trypsinization is a process to lift the attached cells from the cell culture dish. Trypsinization was carried
out by washing the cells in the dish with PBS (no Ca+2 and Mg+2) to remove the media and serum
components from the dish, followed by the addition of 1-3 ml (based on the dish size) of trypsin. The dish
with trypsin was left inside the incubator for 4-5 mins followed by neutralizing the trypsin by adding 4 to
7 ml (based on the dish size) of fresh cell culture media. The trypsin mixed media and cells are centrifuged
at 1000 rpm for 5 mins. After centrifugation, the separated cells were used accordingly. Most of the above
procedures were carried out in a cell culture hood with BSL II specifications. The cell culture dish/device
was left in the incubator maintained at 37 0C & 5% CO2 for cell proliferation/ differentiation. The above
conditions are common for all the cell culture experiments unless explicitly stated.
3.2.2 Maintenance and expansion of stem cells
Mouse embryonic stem cells (mESC) with Hb9::GFP reporter were derived from B6.Cg-Tg
(Hlxb9-GFP)1Tmj/J mice (donated from Dr. Greg Cox Lab, The Jackson Laboratories). The mESC were
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cultured for 3-5 days on a feeder layer of mitomycin-c treated fibroblasts for maintenance and expansion.
This procedure involves culturing/plating mitomycin-c treated mouse embryonic fibroblasts (MEF) in a 60
mm dish (60-70 % confluence) for two days in MEF media (Table 4). After 2 days, MEF media was
vacuumed out of the dish and a vial of mESC (thawed and processed as above) was added to this 60 mm
dish for subculture of mESC on top of the mitomycin treated MEF. The mESC were cultured for 3-5 days
until they reach 80% confluency (round clusters) in mESC media (Table 4) with a fresh media change every
24 hrs.

Media component’s (mESC
media)

For 100 ml

Media component’s (MEF
media)

For 100 ml

Knockout DMEM/F-12
(12660012)

82 ml

DMEM-high glucose (11965092)

89 ml

Knock Out Serum Replacement
(KOSR) (10828028)

15 ml

Fetal bovine serum (FBS), ESCqualified (16141079)

10 ml

MEM-Non-Essential Amino
Acids (NEAA) (11140050)

1 ml

Non-Essential Amino Acids
(NEAA) (11140050)

1ml

GlutaMAX (35050061)

1 ml

(L-alanyl-L-glutamine dipeptide)

2-mercaptoethanol,55 mM
(21985023)

Antibiotic-Antimycotic (sc3690)

1ml

mouse LIF recombinant protein
(10ug/ml) (PMC9484)

100 µl

2-mercaptoethanol,55 mM
(21985023)

100 µl

100 µl

Table 4: Composition of mESC growth/maintenance media & MEF maintenance/growth media
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3.2.3 mESC to motor neuron differentiation
A dish of mESC cultures maintained in mESC media (Table 4) for 3-5 days was trypsinized and
centrifuged. The separated cells after centrifugation were mixed with fresh mESC media and transferred
into an attachment factor (AF) (1x Gelatin, S006100) coated dish and incubated for an hour (1st gravity
separation). AF coated dish is usually prepared by incubating the dish with 0.5 to 3 ml (based on dish size)
of AF for 15 min. Prior to the addition of cells to this dish the excess AF is vacuumed out. After an hour of
first gravity separation, a second gravity separation (for an additional-1 hr) was carried out by gently
pipetting and transferring the media with cells from the 1st gravity separation dish to a new AF coated dish.
Gravity separation helps in the separation of MEF from mESC as MEF (Surface loving cells) tend to settle
faster than the stem cells. At the end of 2nd gravity separation, media with cells were centrifuged at 1000
rpm for 5 minutes. The separated cells (processed as indicated above) were mixed with GeltrexTM
(A1413301), an extracellular basement membrane matrix, at a concentration of 1x1012 cells/ml and further
introduced into the microdevice chamber as indicated below for proliferation and differentiation. The
mESC gel mixture can be differentiated to motor neurons (MN) by culturing the cells in the presence of
ADFNK media (3 µM Purmorphamine a Shh agonist and 1µM Retinoic acid, Table 5). The differentiating
MNs were identified by the presence of Green Fluorescence Protein (GFP), which can be first observed
between day 4 and 5. The HB9::GFP expression increases (fluorescence intensity) gradually and was
maximum around day-7, after which it slowly decreases and no longer present by day-13 (GFP expression
decreases as HB9 expression decreases in postmitotic MNs).

Media component’s (ADFNK media)

For 50 ml

Advanced DMEM/F-12 (12634010)

22 ml

Neurobasal (21103049)

22 ml

Knock Out Serum Replacement (KOSR)
(10828028)

5 mL

Table 5 : Composition of mESC to motor neuron differentiation media (referred as ADFNK media)
40

Table 5 continued
Antibiotic-Antimycotic (sc3690)

50 µl

GlutaMAX (35050061)
(L-alanyl-L-glutamine dipeptide)

0.5 ml

2-mercaptoethanol,55 mM (21985023)

50 µl

Retinoic acid (RA) (stock: 10 mM)
(11017)

5 µl
(1uM)

Purmorphamine (PM) (stock :10 mM)
(1009634)

15 µl
(3uM)

Table 5: Composition of mESC to motor neuron differentiation media (referred as ADFNK media)
3.2.4 mESC to skeletal muscle differentiation in drops
As indicated in the table below (Table 6), three different culture media were explored to efficiently
differentiate mESC to skeletal muscle in a 3D matrix to yield a high percentage of skeletal muscle fibers.
The mESC with HB9::GFP reporter, as described previously, were cultured on mitomycin treated MEF’S
under a variety of mESC maintenance media conditions (Table 6). The mESC were processed as discussed
in the above section with two gravity separations, then mixed with GeltrexTM at appropriate cell density.
Next, 2 µl drops of gel mixed mESC cells are pipetted onto a coverslip (glass or Nunc). The coverslips
were transferred into a 12 well plate or 60 mm dish and incubated for 4 mins for the gel to polymerize.
Following this, suitable media was added to the dish and media was changed every 2 days as indicated in
the following table. The timeline for development and differentiation of mESC to skeletal muscle is
between 21-30 days. The myosin positive skeletal muscle fibers were observed between day 15 to 19 based
on the media compositions used. With time muscle fibers proliferate and mature.
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Culture media C1 161

Days

Culture Media C2 162
Culture Media C2 -A

mESC
mESC media + 2i (1µM- mESC media (only LIF)
maintenance PD0325901 & 3 µM-CHIR99021)
media

Culture Media C2 -B
mESC media + 2i
(1µM-PD0325901 & 3
µM-CHIR99021)

0-2

N2B27 + 1% KSR + 0.1% BSA + DMEM+15% FBS + 3µM N2B27+1%KSR
10 ng/ml BMP-4
CHIR + 0.5% DMSO +
0.1µM LDN-193189

2-6

No Serum media:
Reduced serum:
DMEM + 15% KOSR + 3µM DMEM+1% FBS + 14% KOSR+ 3µM CHIR99021
CHIR 99021+ 0.5% DMSO + + 0.5% DMSO + 0.1µM LDN-193189
0.1µM LDN-193189

6-8

DMEM + 15% KOSR + 0.1 % DMEM+ 1% FBS + 14% KOSR + 0.25 µM PD
BSA + 10 ng/ml HGF + 2 ng/ml 173074 + 0.1µM LDN-193189 + 0.5 % DMSO
IGF-1 + 20 ng/ml FGF-2 + 0.1µM
LDN-193189

8- ~

DMEM + 15% KOSR + 0.1 % DMEM + 2% HORSE SERUM + 1% GlutaMAX +
BSA + 10 ng/ml HGF + 2 ng/ml 1% NEAA
IGF-1 + 20 ng/ml FGF-2

Table 6: Composition of different media

Component

Function

Bovine Serum
Albumin (BSA)
(A7979)

Serum supplement

CHIR99021 (13122)

GSK3-beta inhibitor

PD0325901 (13034)

MEK inhibitor

PD173074 (13032)

FGFR1 inhibitor

LDN193189
(SML0559)

BMP inhibitor

N2 Supplement
(1%) (17504-044)

N2B27 Media

For
50 ml

N2 mixture

25 ml

B27 mixture

25 ml

DMEM/F-12
(11320033)

Neurobasal
(21103049)
B27 supplement
(2%) (17502-048)

Table 7: Different inhibiting factors or morphogens with listed functions used in Table 6 and media
composition of N2B27 media.
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Table 7 continued
Insulin like Growth
Factor-1 (IGF-1)
(250-19)

Growth factor

Hepatocyte growth
factor (HGF) (31523)

Growth factor

Fibroblast growth
factor-2 (FGF-2)
(450-33)

Growth factor

Bone morphogenetic
protein -4 (BMP-4)
(5020-BP-010)

TGF-β signaling
protein

GlutaMAX (1%)

2-mercaptoethanol
(21985023)

50 µl

Table 7: Different inhibiting factors or morphogens with listed functions used in Table 6 and media
composition of N2B27 media.
3.2.5 Myoblasts (C2C12) culture
C2C12 (C2C12 - ATCC® CRL-1772) is an immortalized, mouse myoblast cell line that can be
differentiated into skeletal muscle fibers. C2C12 were cultured in a similar fashion as discussed above for
maintenance and expansion. Contrasting to mESC, maintenance and expansion of C2C12 was simple and
doesn’t involve the use of feeder cells (mitomycin-c treated MEFs), therefore there was no need for any
gravity separation steps. A vial of C2C12 cells was plated in a 60 mm dish (AF coated) and cultured using
C2C12 growth media (Table 8) until they reach a 60-70% confluency before processing for downstream
applications. In the presence of growth media (Table 8), C2C12 cells proliferate profusely, whereas
differentiation media (low serum, Table 8) was used for differentiation and maturation into multinucleated
muscle fibers. On day-0 of the microdevice experiment, C2C12 cells were trypsinized and centrifuged. The
separated cells were mixed with GeltrexTM at 1x104 cells/ml concentration and introduced into the device
as indicated in the next section (2.1.5) for proliferation and differentiation.
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Growth Media

Differentiation Media

DMEM-high glucose
(11965092)

80 ml

DMEM-high glucose
(11965092)

97 ml

Fetal Bovine Serum ESC qualified
(16141079)

10 ml

Equine serum (HyClone
SH30074.02)

2 ml

Antibiotic-Antimycotic
(sc3690)

1 ml

Insulin (1 µM) (0.1%)
(I0516)

0.1 ml

Antibiotic-Antimycotic
(sc3690)

1

ml

Table 8: Growth and differentiation media composition for C2C12
3.2.6 Cell culture and differentiation in the coculture device
Prior to starting cell culture in the coculture device, all the components of the device that come into
contact with culture media or cells need to be sterilized properly to avoid any contamination. Sterilization
was carried out by rinsing and drying (30 min) with 70% ethanol followed by multiple rinses with
autoclaved and filtered (0.45 µm) DI water to remove any leftover ethanol. Before proceeding for
sterilization, a small amount of uncured PDMS was applied 500 µm away from the top and bottom (vias
side) edges (Figure 12a) of the chambers which acts as a greasy barrier between coverslip and device,
enabling a better exchange of gases. After sterilization, the device was left to dry inside the hood with a 30
min of UV treatment to the top and bottom side of the device for improved sterilization. Channels were
vacuumed out for any left-over water droplets before the start of the experiment to keep it completely dry.
Coverslips (~160 µm thick) used for sealing the cell culture chamber were diced into appropriate size using
a dicing saw that can cover the chambers (4 x 2 mm) and interconnecting microchannels (4 x 0.95 mm).
Coverslips were also sterilized by soaking them in 70% ethanol and then rinsed in DI water for 10 mins
respectively, followed by 10 min of UV treatment in the hood. For ease of experimentation and better time
management, while loading the device with cells, the sterilized coverslips were arranged such that they
were easy to access/handle with tweezers.
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Gel mixture with appropriate concentration of mESC and C2C12 were prepared as discussed above
(2.1.3 and 2.1.4). 0.1 - 0.2 µl of pure gel (without any cells) was pipetted onto a coverslip (4 x 0.95 mm)
that can cover the whole region of interconnecting groves. After a 30 second interval, the coverslip is flipped
over the groves thereby filling the groves with gel (without any cell). Immediately after this, 0.8 µl -1 µl of
each gel mixture (cells + GeltrexTM) was aliquoted onto the two separate coverslips diced to the size of the
chambers (MN chamber and Muscle chamber) respectively. After a 30 second wait period, coverslips with
gel cell mixtures (C2C12 & mESC) were flipped over onto respective chambers. A bigger glass covering
the above three small, diced coverslips was placed on them to avoid uneven drying or bubble formation in
the gaps. A pictorial representation of the layout of the coverslips after loading is given below in Figure 12
. Inlet tubes were connected and filled with appropriate cell culture media for growth and differentiation of
mESC and C2C12. If the media flow doesn’t start by itself, a light vacuum was applied to the outlet to start
the flow in the channels.
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a) Cell Chambers before loading with gel mixture.

b) After loading gel with cells, chambers are covered with glass cover
slips

Figure 12: Coculture device layout before and after loading with cells
a & b) 3D representation of empty cell chambers and cell chambers loaded with cells with coverslips covering them. *On the left image, the gap
between the 3 diced coverslips was intentionally left out for ease of understanding of the layout and in actuality, there are close together with minimal
to no gap.

46

3.2.7 Immunocytochemistry and imaging
Immunocytochemistry was performed at required time intervals to stain for different proteins and
transcription factors. First, the coverslips covering the chambers were carefully removed (not disturbing
the spatial distribution of cells + gel) and processed further for fixing and staining. Then, the cell samples
were fixed in 4% paraformaldehyde (for 10 mins) and proceeded further for staining with primary and
secondary antibodies. A detailed process flow of the staining procedure can be seen in Figure 13. The
primary antibodies and the dilutions used are as described in Table 9. The secondary antibodies were used
at 1:500 dilution. For live/dead staining Hoechst-33342 (1:500) and Propidium Iodide (1:1000) were used
by diluting the stain in cell culture media without serum and soaking the sample for 30 mins followed by
PBS wash (repeated twice) and imaging immediately. The stained samples were imaged using Zeiss Axio
Observer Z1 inverted microscope equipped with Zeiss MRm monochrome camera.
Primary Antibodies (Stained for 24 hr)

Dilution

MF20 (MAB4470)

1:100

Anti-Vimentin antibody [EPR3776]

1:250

Cardiac Troponin T (ab8295)

1:100

Anti-GATA4 antibody (ab84593)

1:100

anti Isl-1: Isl-2 (DSHB:39.4D5)

1:100

anti Desmin (DSHB: D3)

1:50

anti-My32 (Sigma: M4276)

1:250

FOXP1 (ab16645)

1:100

Anti-GFP (A11122)

1:250 or 1:200

alpha-bungorotoxinn-555 (B35451)

1:100

Table 9: Primary antibodies utilized and the dilution at which the sample were stained.
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Figure 13: Flow chart of the steps involved in Immunocytochemistry.
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3.2.8 Image quantification and analysis
GFP+ and FOXP1+ cells were counted using ImageJ (NIH). As it was difficult to resolve individual
cells inside the 3D matrix, fluorescent intensities were used to quantify cells. An ‘unsharp mask’ was
applied, followed by cell count (particle analysis). Two way ANOVA in conjunction with an appropriate
multiple comparison test was performed for statistical significance. Myosin+ cells per drop of gel were
counted manually at different z-stacks (heights).
3.3 Results
3.3.1 Diffusion modeling using COMSOL
The intended design of the microdevice fabrication was first modeled in a finite element analysis
software (COMSOL) for optimizing the diffusion profile across the chamber and interconnecting
microchannel. The governing laws in generation of the diffusion profile in the microdevice are Fick’s laws
of diffusion and Navier-Stokes fluid flow equations. Fick’s first law describes the chemical flux in terms
of concentration under the assumption of a steady state analogues to heat transport (Fourier law) and charge
transport (Ohms law). It is commonly represented as
! = −$ &
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F represents the flux of the chemical or material in the study at a concentration C, over a distance x and D
is the diffusion coefficient of the material. Fick’s second law describes the time dependency of
concentration which can be represented in one dimension as follows
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COMSOL a finite element analysis software was used to model the 3D diffusion profile in the
current design of microdevice. Navier Stokes equation was ignored assuming the fluid velocity to be
uniform as it was computationally intense to couple Fick’s law with Navier-Stokes. Inflow boundary
conditions of the opposite media channels were defined to 1 and 0 concentrations which represent a
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normalized source and sink system. Maximum flux in the chamber was limited by the small opening called
“Vias” which create a high diffusion resistance thereby resulting in a gradient concentration profile across
the cell chamber. The flow rate was maintained around 100 µl/hr. A minimum flow rate of 10 µl/hr is
needed to avoid gradient decay in the cell chamber. The diffusion coefficient (D) values of 4.9 x10-8 [m2/s]
(fluorescein163) and 4.3 x 10-10 [m2/s] (rhodamine 164) in water were used in COMSOL simulation, which is
similar to the diffusion of small molecule in water or GeltrexTM (basement membrane extract). GeltrexTM is
a hydrogel which has high water (99 wt. %)165,166 content along with various proteins167. The generated
concentration profile across the chamber is pictorially represented in Figure 14.

Figure 14: COMSOL simulation for fluorescent dye
A spatial concentration profile across the chambers and interconnecting device with opposite source and
sink model.

3.3.2 Fabrication of the coculture device
Three different designs of microdevice were fabricated over time while addressing challenges
generated during cell culture in the microdevice. The basic layout was constant across all designs. Figure
15 represent a 3D model of all the designs fabricated so far with a difference in features from design to
design. Design -2 differs from design-1 only by the presence of posts in a cell chamber, whereas design-3
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differs from design-1 by having posts in a cell chamber as well as the presence of high resistant channels.
Details of the different parameter of each design is listed in Table 10.
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Figure 15: 3D representation of different designs of coculture device
3D illustration of three designs of coculture device fabricated over time with different features. The differences in the dimensions and features are
listed in Table 10.
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Design-1
Interconnecting channels:

Design-2
Interconnecting channels:

Design-3
Interconnecting channels:

Two different length devices on a mask: 1 Two different length devices on a mask: 1 Length: 1 mm
and 2 mm
and 2 mm
Wide :10 µm
Wide :10 µm
Wide :10 µm
Two different depths in a single device:
Two different depths in a single device: 45 Two different depths in a single device: 45 45 and 55 µm
and 55 µm
and 55 µm
Chambers:

Chambers:

Chambers:

1 mm x 1 mm x 100 µm

1 mm x 1 mm x 100 µm

1 mm x 1 mm x 100 µm

Wide media channels:

Wide media channels:

Wide media channels:

9 mm x 300 µm x 375 µm

9 mm x 300 µm x 375 µm

7 mm x 500 µm x 375 µm

High resistance media channels: N/A

High resistance media channels: N/A

High resistance media channels:
5 mm x 45 µm x 80 µm

Posts: 20 µm diameter,

Posts: 20 µm diameter,

Two different heights 45 µm and 100 µm

Two different heights 45 µm and 100
µm

Table 10: Dimensions of various elements in the three coculture designs.
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As an example, the process flow (Figure 16 and Figure 17) of the fabrication of design-3 (Figure
15) is explained. Modeled design of the microdevice was fabricated following various microfabrication
processes in a series. The microfabrication process starts with transferring the design as mask layout which
was achieved using a layout editor program (L-EDIT). The generated layout was fractured and sorted using
ASM2600 and PGSORT which converts the mask layout into a code which is readable by the pattern
generator (GCA3600). A 4” double side polished (DSP) wafer of 500±20 µm thickness was used (p-type
&100) for microfabrication. Before proceeding to fabrication processes the wafers were RCA cleaned. RCA
cleaned wafers were subjected to wet thermal oxidation at 1000 oC for 1.5 hour to generate a 500 nm layer
of oxide on both sides of the DSP wafer. While processing the front side of the wafer, the backside of the
wafer was protected with a layer of photoresist to avoid unwanted etching. Front side of the wafer was
processed to pattern the cell chamber and interconnecting channels. To achieve this wafer was coated with
AZ-1512 photoresist (~2 µm thickness) on both sides followed by development of Mask-1 on the front side.
The developed (Mask-1) wafer was processed with Buffered oxide etch (BOE) solution to etch off the
exposed oxide layer. Photoresist was stripped and a new layer of photoresist (AZ-1512) was applied again
on both sides followed by Mask-2 development and deep reactive ion etching (DRIE) of the exposed silicon
for 45 µm. The 45 µm etched wafer was processed with another series of BOE, photoresist strip followed
by DRIE to etch for another 55 µm (oxide acts as a mask). This resulted in two cell chambers which were
around 100 µm deep with varying depth and height of interconnecting channels and posts (in muscle
chamber) respectively. In the next steps the wafer was flipped and processed on the back side by carefully
aligning the media channels (wide media channels and high resistance channels) to the fabricated design
on the front side of wafer. This process was caried out by coating the backside of wafer with AZ-1512 and
developing the Mask-3 to pattern the design of high resistant channels followed by BOE to etch the exposed
oxide. Photoresist was stripped off and a new layer of thick photoresist (SPR-220: 4 µm) was coated to
develop Mask-4 design for wide media channels. Wide media channels were etched by DRIE (325 µm).
The thick photoresist was stripped off and etched (DRIE) again for 75 µm forming the high resistant
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channels and creating the vias (small opening to diffuse media into the cell chamber). As a final step of
device fabrication/packaging, backside of the diced and cleaned devices were anodically bonded with pyrex
glass (drilled with holes at required positions) to seal the media channels. The device was assembled with
fluidic I/O connectors aligning to the drilled holes on the anodically bonded pyrex before the experiment.
Details of the fabrication processing parameters are illustrated in appendix E
.
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Figure 16: Coculture device process flow - front side
Process flow of front side of the wafer to fabricated cell chamber (with and without posts) and
interconnecting microchannels.
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Figure 17: Coculture device process flow - back side
Process flow for fabricating the media supply channels (wide channels) and high resistant channels for flow
rate control.
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3.3.3 Characterization of the device
The fabricated device was characterized by scanning electron microscopy (SEM) to evaluate the
vias, interconnecting microchannels and posts (Figure 18). Apart from representing structural organization
of the chambers and interconnecting microchannels of the coculture device the following SEM image
(Figure 18) also indicates one of the challenges faced during fabrication of the posts. It was identified that
sonicating the wafer during photoresist removal causes the rupture of posts which was probably due to the
matching wavelength of acoustic signal to the distance between the posts. Therefore, sonication was not
carried out while stripping of the photoresist. As the varying depths and surface profile of channels and
posts were not clear on Figure 18 a high magnification SEM image is included (Figure 19) which represents
the interconnecting microchannels and posts that were formed in the microdevice. The interconnecting
microchannels were 10 µm wide and with different depths (55 and 100 µm). The posts were 20 µm in
diameter and 100 and 55 µm tall separated by 100 µm from the next set of posts.

Figure 18: SEM image of coculture device
Scanning electron microscopy image (SEM) of the front side of the microdevice representing the chambers
and interconnecting microchannels.
58

Figure 19: SEM image of interconnecting microchannels
SEM images of Interconnecting microchannels and posts at a higher magnification to show the different
depth of the microchannels.
To validate the gradient profile generated across the cell chamber in the current microdevice,
chambers were loaded with gel and tested for diffusion of fluorescent dye (Fluorescein and rhodamine)
over time (Figure 20). 1 mM dye solution was prepared by mixing the dye with DI water. Rhodamine was
introduced in one of the media channels of the MN chamber while DI water in other media channel of the
MN chamber. Fluoresceine solution and DI water were introduced in the media channels of C2C12 chamber
in a similar fashion. A concentration gradient was established between the media channels by diffusion of
fluorescent dyes from source to sink. A linear steady state gradient profile was established within 20 mins
and was retained as long as the source and sink conditions were maintained (Figure 20 c). The concentration
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profile generated in the chamber was captured using Zeiss Axio Observer Z1 inverted microscope at
appropriate emission and excitation wavelength for each dye. The fluorescence in interconnecting
microchannel was weak to visualize at the current exposure but a faint gradient profile can be observed in
the interconnecting microchannels.

Figure 20: Gradient generation of fluorescent dyes over time in coculture device
Rhodamine and Fluorescein gradient across the chambers and microchannels at different time interval (ac).By 20 mins (c) the gradient was established and was retained as long as the source and sink were
maintained (confirmed by imaging to be the same at 24 hrs).The fluorescence in microchannel was too
weak to visualize at the current exposure.

60

Figure 21: Quantification of fluorescent intensity (Experimental vs Computational)
Quantification of the normalized fluorescence intensity (pixel intensity) across different position in the
chamber in experiment (brown) vs simulated by COMSOL (blue line) models illustrates the steady state
being established within 20 mins.

To quantify the gradient established in the cell chamber, ImageJ was used to measure the pixel
intensity (normalized intensity) and plotted over the distance of the chamber indicating an approximate
linear profile as predicted by COMSOL model (Figure 21). Parameters such as diffusion coefficient and
concentration were as described in the above section (3.1).
3.3.4 3D culture of the mESC to skeletal muscle in 2 µl gel matrix drops
Various approaches ranging from overexpression of myogenic factor to serum free media
conditions has been adopted in directed differentiation of stem cells into skeletal muscle168. Protocol from
chal et.al161,162 was adapted in the current work for differentiation of mESC to skeletal muscles. This
protocol utilizes a low serum media with various added inhibiting/growth factor at different stages without
any need of transgenic mESC line to overexpress myogenic factor for skeletal muscles differentiation.
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Figure 22: Culture media comparison for differentiating mESC to Skeletal muscle.
a, b, c) mESC differentiated for 16 DIV and stained for fast myosin heavy chain (MY-32) in three different
media conditions. d) quantification of the number of muscle fibers in a drop between different media. e)
MY-32 (strained muscle fibers were visible in the gray scale magnified insert. P values: Nonsignificant (ns)P >
0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Before proceeding to differentiate mESC to skeletal muscle in a microdevice, differentiation time
and media conditions were explored and optimized by differentiating cell in a drop of gel. mESC mixed gel
drops (2 µl) were cultured as indicated in the material and methods at a cell density of 2.4 x 107 cells/ml in
three different media conditions as indicated in Table 6 with varying compositions of different growth and
inhibiting factors. The gel matrix drops were stained for MY-32 (anti-fast myosin heavy chain) on 16 -DIV.
The percentage of skeletal muscle formed in different media conditions were quantified and plotted (Figure
22d). Media C2-B has a significant difference in number of skeletal muscles formed compared to other two
media conditions. A magnified insert (Figure 22e) gives a clear view of the anti-fast myosin-stained muscle
fibers. Therefore C2-B media conditions were utilized from hereon to differentiate mESC to skeletal muscle
in a 3D matrix.
The biggest challenge faced for differentiation of the muscle fibers was retaining the gel drops in
position on the non-coated glass coverslip over time. Round glass coverslips were coated with attachment
factor/serum protein (1% gelatin, FBS, diluted gel) and chemical adhesion agents like silanes (3 glycidoxy
propyl-and 3-aminopropyl triethoxy silane) to increase the adhesion/retention of the gel matrix. Serum or
attachment factor coatings worked partially but majority of the gel drops didn’t retain its structure thereby
it looked more as 2D culture with less to no differentiation, whereas chemical adhesion hampered the cell
growth by killing the cells. Alternatively, Nunc coverslips (Thermo Fischer-174950) were tested, and they
were successful in retaining the drops in place. A disadvantage of using them was they have background
fluorescence which might be not suitable for growing cell in 2D on these coverslips. Though there was
background fluorescence it did not impede the process of fluorescence staining heavily as the cell were
cultured in a 3D matrix. With Nunc coverslips and defined media composition (Media C2-B) mESC were
successfully differentiated to skeletal muscle with formation of muscle fibers starting around 15-DIV and
distinct fibers can be observed by 21-DIV (Figure 23).
Over time these muscle fibers proliferate and differentiate into bundles of skeletal muscle. To
identify the differentiated skeletal muscle, the drops were stained for MY-32 which is a skeletal muscle
63

specific anti myosin antibody and Desmin (D3) an intermediate filament present in muscle tissues. In the
differentiated sample by 21 DIV random fasciculation (twitching) of muscle fibers was observed which
was more prominent with time. To rule out the presence of any involuntary striated muscle, staining for
cardiomyocytes was carried out in the differentiated samples. GATA4 and Cardiac specific troponin-T
(Figure 23 a & b) were negative indicating absence of any cardiac cells thereby ascertaining that random
twitching of muscle fibers were due to change in temperature and pH or presence of any motor unit.
We also observed that gelled drops differentiated on Nunc coverslips have a layer of proliferating
cells on 2D surface at the boundary of the drop acting as an anchor to retain the drop in place. These
proliferating cells have a spindle shaped morphology and stained positive for vimentin (Figure 23 c and d)
confirming that the anchoring cells were fibroblasts.
Though the condition for differentiation of mESC were optimized the majority of the formed
muscle fibers were at the boundary of the gelled drops (Figure 23). A study of the gel drop profile (Figure
24a) by colleague Jonathan Bomar identified that the thickness at the center of the gel was around 0.6 mm.
With an assumption, that the central dense clusters were experiencing nutrient deprivation169 due to high
rate of consumption compared to diffusion, a live dead staining using Hoechst and propidium iodide was
performed and it did show a pronounced cell death at the center of the gel (Figure 24b). It was unclear
whether the pronounced cell death at the center was just due to unavailability of nutrients or a combination
of increased apoptotic/senescence signals from the inner most dead cells.
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Figure 23: Different mESC drops differentiated into skeletal muscle for 21 DIV.
a) stained for skeletal muscle specific (anti-fast myosin heavy chain-MY-32), and Cardiac troponin T. b)
stained for -MY-32, and GATA4. Both a & b stained negative for cardiac proteins and positive for skeletal
proteins confirming the differentiated muscle fibers to be skeletal muscle. c&d) stained for MY-32 and
Desmin along vimentin (fibroblasts) .
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Figure 24: Gel matrix profile and cell viability in gel matrix.
Profile of the gel matrix measured using a profilometer indicate varying thickness across the gel with
maximum thickness of 0.6 mm at the center. b) mESC differentiating to skeletal muscles stained on 15 DIV
for live dead staining indicate pronounced dead cell at the center of the gel drops compared to the periphery.

To avoid this cell death at the center, seeding cell density was lowered such that muscle fibers can
be formed all over the drop rather than just the periphery. As indicated in the material and methods feeder
dependent culture of mESC in maintenance media was carried out before the experiment. Two different
seeding density (2 x 104 and 2 x 107) were mixed in gel and 2 µl drops were plated on Nunc coverslips and
differentiated for 30 DIV followed by staining with MY-32 (Figure 25).
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Figure 25: Effect of seeding density
Two different seeding densities for differentiation of mESC to skeletal muscle in gel matrix drops. Drops
are fixed and stained for My-32 at 30 DIV. a&c) cells seeded at a lower cell density to allow the formation
of muscle fibers at the center of the drop. b&d) a normal seeding density as control.
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The low seeding density did not help in formation of the muscle in the central region of the drop
and moreover the quantity of fibers formed decreased drastically compared to the normal seeding density.
This was similar to U2OS and MN differentiation where a threshold cell density was needed for uniform
differentiation and distribution. Apart from this, it was also observed that mESC to skeletal muscle
differentiation in gel drops results in extensive restructuring (uniform gel diameter in Figure 25a & b
compared to Figure 25c & d) of the extracellular matrix which can be attributed to the fusion of the
myocytes to muscle fibers. Extracellular matrix remodeling is a dynamic phenomenon involved in various
functions such as homeostasis, morphogeneis170, disease progression171 and structural support. Results from
the later section (3.3.5.1), i.e., differentiating C2C12 in a microdevice, it was identified that absence of
structural support while the myocytes are fusing to form myofibers results in shrinkage (Figure 28a) of gel.
These results indicate that in case of gel matrix drops, a pronounced muscle fiber formation only at the
periphery (Figure 23) of the gel can be due to a combination of lack of sufficient number of live cells and
also due to the absence of structural support at the center of the gel matrix.
3.3.5 C2C12 & mESC culture in coculture device
3.3.5.1 Viability of cells in coculture device
As the differentiation timeline of mESC to skeletal muscle (21 DIV) and mESC to MN (7 DIV)
being different from each other and with challenges to uniformly distribute skeletal muscle fibers inside a
gel drop, a new muscle cell line (C2C12) was used for coculture studies. The C2C12 cells as described in
material and methods are immortalized mouse myoblast cell lines which has a differentiation timeline
similar to that of MN (7 DIV). Timeline of differentiation of C2C12 in 3D gel matrix is mostly governed
by cell density i.e., a high seeding density (≥ 2 x 107 cell/ml) results in formation of myotubes within 48
hours even in presence of growth media without any need of differentiation media as seen from the phase
contrast images Figure 26. Therefore, to increase and match the differentiation timeline to MN
differentiation, C2C12 cell seeding density of 1 x 104 cell/ml were used in coculture device experiments.
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Figure 26: C2C12 2D vs 3D
C2C12 on a) 2D surface and b) In a 3D Gel matrix. Within 48 hrs the C2C12 in 3D start differentiating into
myotubes whereas they still exist as myoblast on a 2D surface

Cell lines (mESC and C2C12) were differentiated separately in the coculture device to validate the
viability/differentiation of cells in the device. In case of C2C12 the viability was identified by staining for
propidium iodide/Hoechst-33342 (propidium iodide stains for dead cells, Hoechst-33342 stains for all
cells). The viability/differentiation of MNs were observed by the expression of eGFP (presence of uniform
eGFP indicates healthy differentiation). As mESC to MN differentiation has been successfully optimized
by Demers et.al99 in a gradient microfluidic platform, similar results were observed in the current coculture
design (Figure 27) as well. Figure 27 represents the healthy differentiated MNs on 7 DIV (expressing eGFP)
in a cocultured device with interconnecting microchannels.
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Figure 27: mESC to MNs in coculture device
a) mESC to MN (7 DIV) differentiation in the coculture device. b) Artificially enhanced contrast to view
the interconnecting microchannels adjacent to the chamber.

But the C2C12 differentiation in the coculture device was challenging. As observed from Figure
28a when gel mixed C2C12 were cultured in the design-1 device as prescribed in material methods for 5
DIV, it resulted in a shrinked gel inside the chamber. This can be attributed to the absence of the stable
structural support when myoblasts were fusing to form myotubes. The shrinkage of gel was resolved by
introducing posts/pillars ( Figure 19: design 3 of microdevice) in the muscle chamber (Figure 28b,c) which
acts as anchoring point for the differentiating myoblasts and thereby avoid shrinking or restructuring of the
gel as they are differentiating. Even distribution of nuclear (Hoechst) stain across the cell chamber (Figure
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28b compared to Figure 28a) suggests that the structural support is essential for uniform distribution of
differentiating skeletal muscle fibers across the chamber.

Figure 28: C2C12 grown in two different designs of the muscle chamber (gel shrinkage).
a) cell chamber without posts representing a shrinking/remodeled gel by C2C12. b) cell chamber with posts
which provide adhesion points for the differentiating myoblasts which prevent restructuring of the gel. c)
A gray scale image to show the interconnecting microchannels of the coculture device with posts.
3.3.5.2 Common challenges in coculture experiments
Various challenges were encountered while testing and culturing cells in coculture device. A
pictorial documentation is represented in Figure 29 to easily identify and alleviate the cause in future design
and studies. Following aseptic conditions while performing the experiment, contamination (stained for
Hoechst-33342 show a uniform spherical structure of bacteria which are smaller than nucleus) as shown in
Figure 29c can be avoided. Adhering to the loading protocol, the air bubble in chambers, i.e., absence of
uniform staining for Hoechst-3342 with blank dead space indicating the gel being pushed out due to the air
bubbles (Figure 29 e, f) can be prevented. Uneven drying or left-over ethanol/H2O2 during sterilization can
result in uniform dead cells in the chamber by 1 DIV (Figure 29a: Stained positive for propidium iodide).
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Interrupted or no flow of media in the supply channels results in dead cell predominantly in the center of
the chamber (Figure 29b). Excessive wait time between the gel loading and sealing with glass coverslips
results in dried out gel at the center (Figure 29d: gray scale view of eGFP of MN to show the blank dead
region at the center.)
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Figure 29: A pictorial representation of various challenges faced in a coculture experiment.
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Optimizing the fluid flow system was also important for uninterrupted culture to avoid unexpected
challenges. Two different gravity flow systems were used in supplying media at a constant flow rate
(average flow rate of 100 µl/hr) as represented in Figure 30. The design (Figure 15, design 1 & 2) of
coculture device used in Figure 30b doesn’t include any high resistant channel for flow control thereby an
external flow resistant in the form PEEK (20 mm long with 64 µm diameter opening) tubing was used to
control the flow rate. An interconnecting thin-walled PTFE (teflon) tubing (300 µm opening) connect the
reservoirs to the inlets on the device. The biggest drawback of this model was the generation of air bubbles
in the interconnecting I/O fitting due to the dissolved gases in cell culture media thereby restricting the fluid
flow. Though this system was successful, reproducibility of constant flow was very low. Thereby gravity
flow system with a high resistant channel (Figure 30a) on chip was used which has high reproducibility
compared to the other model. The dimensions of the high resistant channels in design -3 (Figure 15 and
Figure 30a) are 5 mm x 45 µm x 80 µm. The 5 ml media reservoirs are attached directly onto the device.
The flow rate changes with height of media in the reservoir. For a better flow control and run multiple
devices in parallel a self-sustaining cell culture system was designed using piezo pumps and in-house fluid
controller system. Details of the system and its functioning are furnished in appendix -G.
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Figure 30: Two gravity flow system involving two different designs of the coculture device
a) Design-3 device with high resistance channel on chip b) Design -2 device without high resistance
channel, thereby a PEEK tubing of the chip acts as fluid flow controller.

3.3.5.3 Differentiation of LMC motor neurons in coculture device
Coculturing two different cell lines (mESC and C2C12) in a single device with interconnecting
microchannels was carried out to see the effect of C2C12 on MN differentiation. For culturing cells in the
coculture device, the seeding density of mESC was maintained at 2 x 107 cells/ml and C2C12 at 1 x 104
cells/ml. Gel mixture (GeltrexTM and cells) was prepared and loaded into the cell chambers of the device as
described in material and methods. Based on our previous work99 concentration of morphogens (retinoic
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acid: 1 µM, purmorphamine (PM): 3 µM) in ADFNK media (Table 5) is maintained constant across the
MN cell chamber without any gradient for uniform distribution of MNs in the cell chamber. C2C12 chamber
is supplied with growth media (Table 8) for cell proliferation. Changes in the motor neuron chamber
(formation of MN) was tracked by the expression of HB9::GFP (eGFP). eGFP expression in the motor
neuron chamber starts by 5 DIV and decreases down by 12 DIV (Figure 31b). The HB9::GFP fluorescence
intensity follows similar trend to that observed in in vitro (Figure 31b), i.e., overtime, expression of HB9
protein in the differentiated cells (MNs) decreases and thereby GFP expression also decreases. Due to the
absence of any fluorescence reporter protein in C2C12 cell line, their progress cannot be visualized in a
similar fashion to that of MN (Figure 31a). On the 12th day of coculture experiment the device was fixed
and stained for myosin (MF-20) and GFP (anti-GFP) following the protocol as discussed in material and
methods. Anti-GFP (green) was expressed only in MN chamber and myosin was expressed only in C2C12
(magenta) chamber. This successfully represent the coculture of two different types of cell type in a single
device.
A comparison of the antibody staining between coculture device and control device is represented
in Figure 32 to understand the effect of muscle of cells on differentiating motor neurons. Figure 32a
represents the fixed and stained (for FOXP1, myosin and anti-GFP) coculture device with MNs and C2C12
in the adjacent chambers, whereas Figure 32b, represent the control, where MNs are differentiated in both
chambers. The C2C12 cells in the coculture device stained positive for myosin (anti-MF20: Figure 32a.ii)
confirms the presence of differentiated myotubes with myosin fibers. A high magnification image of the
muscle fibers formed in the coculture device is present as Figure 32d where myosin-stained multinuclear
muscle fibers can be observed. Though the nuclear staining was not performed the multiple dark spherical
spots in a long muscle fiber indicate the presence of nuclei. Interestingly, C2C12 cells were also stained
positive for FOXP1 (Figure 32a.i) and from literature it was identified that FOXP1 is expressed in skeletal
muscle, and it act as transcriptional repressor172 for gene expression governing proliferation and
differentiation.
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Figure 31: Coculture of MNs and C2C12
a) Time-lapse imaging of MN development at different days showing the expression of endogenous GFP
(eGFP). Before 5-DIV the fluorescence intensity was zero. After 12 DIV of coculture experiment, the cells
(both MN and C2C12) were fixed and stained for myosin and GFP. b) Quantification of HB9::GFP
expression (normalized intensity) at different time interval indicate maximum intensity to be around 10
DIV and the eGFP expression reduces by 12 DIV .RA: retinoic acid (1 µM),PM: purmorphamine (3µM).
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FOXP1 is the transcription factor expressed in variety of the cells and is involved in tissue
specification173 and development174. In case of MNs, only LMC motor neuron express FOXP1175. Presence
of FOXP1 protein in a differentiated MN neuron is used as an identification of the columnar subtype of the
MNs. Therefore the merged images (MN chamber- Figure 32a.iii) confirm the presence of cells stained
positive for FOXP1 and HB9::GFP and corroborate that they belong to LMC motor column subtype. A
higher magnification image of colocalization of FOXP1 and GFP in the MNs is represented in Figure 32c.
Soma and neurites of the MNs can also be observed in the magnified inset (Figure 32c). LMC motor column
motor neurons are further sub-divided into LMC- l (lateral LMC, LMC-l stains positive: FOXP1, LHX1)
innervating dorsal limb muscles and LMC-m (medial LMC, LMC-m: FOXP1, Isl1/2) innervating ventral
limb muscles. Though the above results (Figure 32a, c) confirm that they belong to LMC further staining
with LHX1 is needed to identify which subclass of LMC MNs were formed in the coculture device.
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Figure 32: Immunostaining for LMC MNs
a) coculture device with MN and C2C12 in adjacent chambers with interconnecting microchannels stained
for FOXP1 & GFP (in case MN) and FOXP1 and Mysoin (in case of C2C12). b) Control device with MNs
in adjacent chambers stained for FOXP1 and GFP. c) Magnified (20x) view of a cluster of MN indicating
the colocalization of both FOXP1 and GFP in MNs. Soma and neurites of the MNs can be observed clearly
at this magnification. d) Magnified (20x) view of the myofibers formed in the C2C12 chamber stained
positive for myosin (MF20).The myosin stained image also indicate the presence of more than one nucleii
(dark spherical structures) in a single fiber. *Interconnecting microchannel are artificially indicated to
represent the two chambers are from a single device.

Quantification of the % LMC MNs (Figure 33) formed in coculture device vs control device was
carried out to see if there was any noticeable effect of C2C12 on differentiating MNs. It was identified that
in presence of C2C12 (coculture device) the number of LMC MNs (Figure 33) formed were 40.58 % (p ≤
0.001, n = 5, two-way ANOVA-sidak test) more than the one without of C2C12 (control device). This was
a prominent result as differentiation of LMC in an in vitro culture has been always challenging and most of
the high yielding LMC in vitro culture employ a targeted specific gene overexpression154 to guide the stem
cells to LMC fate. Increase in the number of LMC MNs (69 % ± 9) in coculture device compared to control
device (28.4 % ± 9) (Figure 32c) indicate that signal transduction between C2C12 and MNs through the
interconnecting microchannels was directing the differentiating mESC toward LMC motor column fate.
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Figure 33: Quantification of LMC MNs (Control vs Coculture device)
FOXP1 and GFP positive motor neuron (LMC-MN) in two different devices, i.e., in presence (coculture)
and absence (control) of C2C12. Quantified data indicates an increase in LMC MN in coculture device
compared to control device. Sample size n=5, P values: Nonsignificant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P
≤ 0.001.

Though the factors or molecules involved in this fate determination are difficult to identify from
the current coculture system, a secretome (secreted proteins) analysis of the skeletal muscle from the
literature has indicated the presence of significant amounts of FGF176, GDF177, TGF- β178 and various other
proteins179. Some of these released factors (FGF, GDF, TGF- β) from C2C12/skeletal muscles are also the
same known morphogens involved in anterior- posterior (AP) patterning of neural tube (Figure 11a).
Gradients of FGF-8 and GDF-11 from tail bud180 are involved in Hox gene activation to assign the columnar
identity to the ventrally differentiating MNs in a developing neural tube. Tail bud is predominantly
composed of undifferentiated stem cells of paraxial mesodermal origin and skeletal muscles are also
differentiated from the paraxial mesoderm cells. This suggest that signaling molecules from skeletal
muscles are involved in guiding the MNs towards specific subtype. Therefore, results indicate the
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importance and need of coculture system to understand the complex underlying mechanisms and explore
for any unknown factors contributing to the fate determination of MNs.

Figure 34: Axon outgrowth into interconnecting channels
a)10 DIV coculture device with native GFP(eGFP) expression in MN chamber and C2C12 in the adjacent
chamber (dotted box indicate the chamber outline). b) a magnified insert with artificially enhanced contrast
to visualize presence of axons in chamber and microchannels
Apart from identifying the motor neuron subtype, formation of neuro muscular junction (NMJ) was
also explored using the coculture device. A 10-DIV eGFP expression by the MN has indicated the neurites
/axons entering the microchannels and travelling towards the C2C12 chamber (Figure 34). As expression
of eGFP mitigates overtime imaging the channels for neurites travel was difficult to visualize. To identify
the formation of NMJ, the above device (Figure 34) was cultured for 15 DIV and fixed with 4 %
paraformaldehyde for 10 mins and stained with alpha bungarotoxin-555 (1:200, diluted in blocking buffer)
for 30 mins before permeabilization and primary antibody staining (Figure 35). Conjugated bungarotoxin
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stains the nicotinic acetylcholine receptors (AChR) present on the C2C12 muscle fibers in a completed
neural circuit. Absence of the NMJ staining (no red color) in the C2C12 chamber by 15 DIV (Figure 35)
represents that complete neural circuit was not yet formed inside the coculture device. The unsuccessful
NMJ staining along with distance traveled by axon by 10 DIV (Figure 34b) being only around 300 µm
indicates the need of culturing for longer duration (around 20-30 DIV) for formation of functional NMJ.

Figure 35: NMJ staining using bungarotoxin
Device stained for NMJ using alpha bungarotoxin-555 at 15 DIV resulted in a negative staining without
any NMJ visualization. A weak endogenous GFP (eGFP) can be observed in the MN chamber.

3.4 Conclusions
In this chapter a novel microfluidic coculture system was designed and fabricated. The designed device can
generate concentration gradient across the device for drug assays or neural tube patterning with tailored
environment. Optimization of growth media for differentiation of mESC to skeletal muscle in a gel drops
indicated the difference in differentiation time between MN (7-DIV) and skeletal muscle (21-DIV).
Moreover, it was identified that the differentiation of mESC to skeletal muscles in a 3D matrix resulted in
the formation of muscle fibers only in the periphery of the gel thereby limiting us to move on to a
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differentiated muscle cell line (C2C12) for coculture studies. A successful differentiation of MNs and
C2C12 (in 3D) in a coculture device illustrates its capability to culture two different types of cells in a
single device. In presence of C2C12, around 69 % of the MNs formed belong to LMC motor column
subtype, compared to 28 % in case of control device. This indicates the signal transduction from C2C12 in
directing the differentiating MNs towards specific subtype (LMC). Further research is needed to identify
signaling molecules, but the current results prove the ability of the microfluidic platform in exploring the
effect of intercellular communication during neural development. With its ability to create concentration
gradients this tool can be easily used in drug development and in understanding neurodegenerative disease
where LMC motor neurons are the first targets of degeneration.
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CHAPTER 4 : CONCLUSIONS AND FUTURE DIRECTIONS
4.1 Conclusion
The advent of microfluidic technology has provided biologists with a valuable tool in exploring different
aspects of the in vivo system in an in vitro study. Using a microfluidic gradient generating microsystem
(Chapter 2), motor neurons exhibiting ALS phenotype (cytosolic TDP43 aggregates) were rescued from
degeneration by exposing them to rapamycin. As the cell cultures were carried out in a 3D environment,
they resemble the in vivo conditions more appropriately than a 2D culture. Furthermore, we have identified
the dosage response range of rapamycin (0.4-1.0 µM) in rescuing MN from degeneration and the toxicity
of rapamycin from a single drug assay experiment.
Apart from the above, an anti-osteosarcoma drug (doxorubicin, cisplatin & methotrexate) assay was carried
out using the same microfluidic (chapter-2) gradient generator. Initial analysis indicated promising results
of drug assay and the identified LD-50 values from the assay were similar to that of the literature. However,
tumor biology seems to be more complicated as the data obtained was not reproducible. Overall, from the
above two studies (chapter 2), the ability of the microdevice to culture cells in parallel and perform drug
titration simultaneously elucidates the high throughput efficiency of the microdevice.
Building on this idea, we designed and fabricated a microfluidic platform (Chapter 3) capable of 3D
culturing two different cell types separately but still in contact for cell-cell communication. Muscle cells
(C2C12) and mESC were cocultured using this microfluidic platform. The coculture study has revealed that
the signals from muscle cells direct the differentiating stem cells into limb innervating motor neurons
(LMC) predominantly. Though the definite signaling moieties involved are not known from this
experiment, the secretome analysis of muscle cells from the literature (secretome analysis by Hartwig et al.
and other groups)176,181,182 have indicated the most suitable ones to be FGF and GDF. The reason for
inferring these two to be the contributing factors is, FGF and GDF are involved in Hox gene patterning
(subtype specification of MN) in the developing neural tube. With further analysis and experimentation,
this area can be explored to identify the contributing factors. Nevertheless, this device can also be adopted
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and explored in understanding the effect of intercellular communication between different biological
systems.
4.2 Future directions
Here I present a few examples of how the microfluidic systems in the study can be utilized further to explore
and understand the underlying biochemical/ physiological process.
4.2.1 Patient-specific disease modeling
Though most of this current study involves microfluidic cell culture using mouse cell lines, the microfluidic
device is also capable of culturing cell lines from different species. Mouse cells were preferred in this study
because of well-studied and established protocols for cell differentiation. Both microfluidic designs from
chapters 2 & 3 can be utilized in patient-specific disease modeling and phenotypic drug screening. Using
human iPSC, different cell types can be differentiated in the coculture device and can be used to study the
effect of drug treatment on neighboring cells/tissues when only a single chamber of cells/tissue is exposed
to drug assay. Thereby the coculture device act as an invaluable tool to maximize phenotypic screening of
drugs before moving to human trials.
4.2.2 Identifying the other MN and staining for motor neuron pool
As the subtype specific MN differentiation (chapter 3) is still an ongoing research, a few specific
experiments listed below can be utilized to understand the unanswered questions.
a) In the presence of muscle cells, 70 % (chapter-3 Figure 21c) of the differentiated MNs
show LMC motor column identity. Therefore, columnar identity of the remaining 30 % of
MNs should be explored. This can be achieved by staining for MMC (Lhx3), HMC (Mnx1)
and PGC (pSmad) motor column markers.
b) Identifying the LMC subtype, and motor pool identity (MN targeting specific muscle) of
the LMC MNs will help in identifying the specific set of motor neurons generated in the
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microdevice. This can be achieved by staining for LHX1 (to identify the subtype of LMC)
and Etv4, Nkx6.1, Pouf3f1 (to identify the motor pool)
c) Time-dependent staining of the differentiating cells for different HOX genes can help us
in understanding the effect of signaling molecules from muscle cells and the underlying
mechanism involved in determining the lineage specificity of MN.
4.2.3 Modification to current coculture device design for NMJ visualization
Though the current coculture device has indicated the axon growth from MN chamber to muscle chamber
(Figure 34), a functional NMJ formation was not seen in the microdevice (Figure 35). This can be addressed
as follows
a) One possibility for not observing the NMJ formation was that the duration of experiments (15
DIV ) was not sufficient to form a functional NMJ. Thereby carrying out a longer culturing
time (21-30 DIV) can alleviate this probability.
b) Due to the deep interconnecting microchannels (Figure 19), visualization and tracking of the
axon outgrowth was difficult. A minor modification to the device etching step can help in
generating shallow interconnecting microchannel, thereby enabling us to track and study axon
guidance.
c) Because of the dense muscle fibers and imaging limitations in the microdevice, identifying
NMJ solely using alpha-bungarotoxin staining for nicotinic acetylcholine receptors (AChRs)
may not be ideal. An alternative to overcome this problem would be to stain for pre-synaptic
segments, i.e., staining for neurofilaments (using anti-2H3) and axons (using anti-SV2) will
increase the possibility of finding post-synaptic AChRs when stained using bungarotoxin.
4.2.4 Secretome collecting microfluidic device
The possibility of FGF and GDF to be the contributing factors in generating LMC is compelling, but it is
not yet confirmed from the coculture experiment. This opens up new avenues of study using coculture
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devices. The current design needs to be modified to accommodate for collection of signaling molecules
from the interconnecting microchannels. The collected secretome is prepared and processed for a LC - mass
spectrometry similar to that of Robert et.al183 and the results are compared to the protein database (Uniport).
As the signaling molecules are not collected from the bulk media, the signal to noise ratio will be better in
case of mass spectrometry analysis and identification of trace amount of protein will be more promising.
This microfluidic platform will be a useful tool in understanding and identifying the secreted signaling
compounds in various coculture systems.
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APPENDIX A
LIST OF ABBREVIATIONS
eGFP

Endogenous/enhanced green fluorescent protein

MN

Motor neuron

PDMS

poly(dimethylsiloxane)

PMMA

Poly methyl methacrylate

ALS

amyotrophic lateral sclerosis

SOD1

Superoxide dismutase 1

TDP-43

TAR DNA-binding protein-43

FUS

Fused In Sarcoma

mTOR

Mammalian target of rapamycin

ULK1

Unc-51 like autophagy initiating kinase

CNS

central nervous system

Shh

sonic hedgehog

BMP

bone morphogenic protein

Wnt

wingless-related integration protein

RA

retinoic acid

FGF

fibroblast growth factor

GDF

growth differentiation factor

HOX

Homeobox

LMC

lateral motor column

MMC

median motor column

HMC

hypaxial motor column

PGC

preganglionic motor column

MyHC

myosin heavy chain
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MyLC

myosin light chain

EDTA

Ethylenediamine tetra acetic acid

ESC

Embryonic stem cell

myc

Mitomycin-c

MEF

mouse embryonic fibroblast

mESC

Mouse Embryonic stem cell

hESC

human Embryonic stem cell

BOE

Buffer oxide etch

DRIE

Deep reactive ion etching

DMSO

Dimethyl sulfoxide

iPSC

Induced pluripotent stem cells

DV

Dorso-ventral axis

PBS

Phosphate buffer saline

DIV

Days in vitro

PEEK

Polyether ether ketone

PTFE

Polytetrafluoroethylene (Teflon)

NMJ

Neuro muscular junction

HMDS

Hexa Methyl DiSilazane

DSP

Double side polished
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APPENDIX B
GRADIENT GENERATING MICROFLUIDIC DEVICE PROCESS FLOW
Process
1.Starting
material

Equipment/Materials

4” silicon wafer
RCA Bench:
Base bath:
H2O: NH4OH: H2O2

2. RCA Clean Acid bath:
H2O: H2SO4 : H2O2

Settings/Specifications

Comments

DSP
P-type
Si
wafers
Resistivity: 0-100 Ω-cm
Orientation: 100
Place wafer in wafer carrier and
submerge in
1.Base bath:10min @ 75°C
2.DI Water bath: Rinse
3.Acid bath:10min @ 75°C
4.DI Water bath: Rinse
5. Dry with N 2
5 min. Dry Ox. @ 1000ºC

3.Wet oxidation
Oxidation furnace

1.5 hr. Wet Ox. @ 1000ºC
5 min. Dry Ox. @ 1000ºC

Target: 500nm

4.HMDS coating HMDS vacuum hot plate HMDS vapor prime at 90ºC for
system
90s
5.Spin photoresist Teflon chuckAZ1512
(3 ml)

Spinner parameter in Appendix
C
Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle

6.Expose and
develop

Karl Suss MA6
Chamber Mask

7. Etch oxide

BOE bath

Expose for 12s (85 mJ Dose)
Develop in MIF300 (TMAH)
for 30 sec

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle
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Dry with N 2

UV expose without mask.

8.Strip photoresist

Strip photoresist
remover

using

PG

or
Acetone/IPA/MeOH/DI
9.Protectwafer Teflon chuck
backside and spin
photoresist on
front side
AZ1512 (3 ml)

10. Expose and Karl Suss MA6
develop
Via Mask

11. DRIE vias STS DRIE

Spinner parameter in Appendix
C
Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle
Expose for 12s (85 mJ Dose)
Develop in MIF300 (TMAH)
for 30 sec
15 minutes of etch: Multiples of
5min etch with alternative 30sec
hold-cool in between.
Start with passivate layer and
end on etch. (DRIE parameter 60 µm etch
in Appendix c)

12.Strip
photoresist

13.DRIE
chambers

UV expose without mask.
Strip photoresist using
remover
Acetone/IPA/MeOH/DI
STS DRIE

PG
or

15 minutes of etch: Multiples of
5min etch with alternative 30sec
hold-cool in between.
Start with passivate layer and 100 µm etch
end on etch. (DRIE parameter
in Appendix c)
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14. Spin
photoresist on
backside to
protect from BOE

Teflon
(3ml)

chuck AZ1512 Spinner parameter in Appendix
C
Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle

15. Expose and High resistance channel Expose for 12s (85 mJ Dose)
develop
mask
followed by BOE and

Develop in MIF300 (TMAH)
for 30 sec

BOE
6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle

16. Strip
photoresist

UV expose without mask.
Strip photoresist
remover

using

PG

or
Acetone/IPA/MeOH/DI
17. Spin

Teflon chuck

photoresist for SPR220 (4ml)
deep channels

HMDS vapor prime
Spinner parameter in Appendix
C
Rest: 30 sec on spinner
Soft bake for SPR220 details in
Appendix C

18. Expose and Karl Suss MA6
develop
Deep channel mask

Expose for 60s (385 mJ Dose).
Divided into 4 cycles with 30
sec hold time in between
Wait 1 hr before developing
Develop in MIF300 (TMAH)
for 300 sec

19. DRIE Deep STS DRIE
channels

Multiples of 5min etch with
alternative 30sec hold-cool in
between.
Etch: 335 µm
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Start with passivate layer and
end on etch. DRIE parameter
(Appendix c)

20. Strip
photoresist

21. DRIE high STS DRIE
resistant channels
and vias

UV expose without mask.
Strip photoresist using
remover
Acetone/IPA/MeOH/DI

PG
or

Multiples of 5min etch with
alternative 30sec hold-cool in
between.
Start with passivate layer and
end on etch. DRIE parameter Etch: 70 µm
(Appendix c)

22. Etch oxide BOE bath

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle
Dry with N 2

23. Anodic
bonding

T = 420ºC
V= 1100V
t = 5-10min
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APPENDIX C
GENERAL MICROFABRICATION PARAMETERS
1) Soft bake for SPR220: 300 seconds at 115 0C
Ramp temperature of the hot plate to 130 0C once it reaches the set temperature decrease the
temperature to 115 0C. Transfer the wafer on to the wafer pins and let the temperature decrease to 115 0C
while wafer is on the pins. Switch on the vacuum and let the wafer contact the hot plate. Set timer for 300
sec. After bake, raise the pins and let the wafer sit there for at least 5 mins to avoid thermal shock. Transfer
the wafer onto a lint free wipe let it sit for 30 min before exposure.
2) STS DRIE parameters
Etch

passivation

C4F8 flow rate (sccm)

0

110

SF6 flow rate (sccm)

130

0

RF Power, 13.56MHz,
Coil

900 W, ramp rate 0 W/min

800 W, ramp rate 0 W/min

RF Power, 13.56MHz,
Platen

16 W, ramp rate 0.1 W/min

0 W, ramp rate 0 W/min

Helium backside
cooling

9500 mTorr, Flow rate: 5 (min) to 40 (max) sccm

3) Photoresist spinner parameters
AZ1512

SPR220

Spread: Ramp to 1000 RPM in 5 sec, hold
for 10 sec

Spread: Ramp to 500 RPM in 10 sec, hold
for 10 sec

Spin up: Ramp to 3000 RPM in 5 sec, hold for
30 sec

Spin up: Ramp to 1500 RPM in 10 sec, hold for
45 sec

Spin down: Ramp to 1000 RPM in 5 sec, hold
10 sec, ramp to 0 RPM in 5 sec

Spin down: Ramp to 500 RPM in 5 sec, hold 5
sec, ramp to 0 RPM in 5 sec
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APPENDIX D
GRADIENT GENERATING MICROFLUIDIC DEVICE MASK
Device was designed by Dr. Chris Demers. Same Masks were used in fabrication

108

APPENDIX E
PROCESS FLOW OF CO-CULTURE DEVICE DESIGN-3

Process
1. Starting
Material

Equipment/Materials

4” silicon wafer

Settings/Specifications

Comments

DSP P-type Si wafers
Resistivity: 0-100 Ω-cm
Orientation: 100

RCA Bench:
Base bath:
H2O: NH4OH: H2O2
2. RCA Clean

Acid bath:
H2O: H2SO4 : H2O2

Place wafer in wafer carrier
and submerge in
1.Base bath:10min @ 75°C
2.DI Water bath: Rinse
3.Acid bath:10min @ 75°C
4.DI Water bath: Rinse
5. Dry with N 2

3. Wet
oxidation

5 min. Dry Ox. @ 1000ºC
Oxidation furnace

1.5 hr. Wet Ox. @ 1000ºC
5 min. Dry Ox. @ 1000ºC

4. HMDS
Coating

HMDS vacuum hot plate
system

HMDS vapor prime at 90ºC
for 90s

5. Spin
photoresist

Teflon chuckAZ1512 (3
ml)

Spinner parameter in
Appendix C

Target: 500nm

Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle
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6. Expose and
develop

Karl Suss MA6
Chamber V9 (Mask-1)

7. Etch oxide

BOE bath

Expose for 12s (85 mJ Dose)
Develop in MIF300 (TMAH)
for 30 sec

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle
Dry with N 2

8. Strip
photoresist

UV expose without mask.
Strip photoresist using PG
remover
or
Acetone/IPA/MeOH/DI

9. Protectwafer
backside and
spin
photoresist on
front side
10. Expose and
develop

Teflon chuck
AZ1512 (3 ml)

Spinner parameter in
Appendix C
Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle

Karl Suss MA6

Expose for 12s (85 mJ Dose)

Posts (Mask-2)

Develop in MIF300 (TMAH)
for 30 sec
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11. DRIE vias

STS DRIE

15 minutes of etch: Multiples
of 5min etch with alternative
30sec hold-cool in between.
Start with passivate layer and
end on etch. (DRIE parameter
in Appendix c)

45 µm etch
12. Strip
photoresist

13. Etch
exposed oxide

UV expose without mask.
Strip photoresist using PG
remover or
Acetone/IPA/MeOH/DI

BOE

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle

14. Strip
photoresist

UV expose without mask.
Strip photoresist using PG
remover
or
Acetone/IPA/MeOH/DI

15. DRIE
interconnecting
channels

STS DRIE

Multiples of 5min etch with
alternative 30sec hold-cool in
between.
Start with passivate layer and
end on etch. DRIE parameter
(Appendix c)

Etch: 55 µm
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16. Strip
photoresist

UV expose without mask.
Strip photoresist using PG
remover or
Acetone/IPA/MeOH/DI

Wafer is flipped and processed on the back side
17. Spin
photoresist

Teflon chuck
AZ1512 (3 ml)

Spinner parameter in
Appendix C
Rest: 15 sec on spinner
Soft bake: 90ºC for 90sec,
vacuum cycle

18. Expose and
develop

Karl Suss MA6

Expose for 12s (85 mJ Dose)

High Resistance channels Develop in MIF300 (TMAH)
for 30 sec
(Mask-3)
19. Etch oxide

BOE bath

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle
Dry with N 2

20. Spin

Teflon chuck

HMDS vapor prime

photoresist for
deep channels

SPR220 (4ml)

Spinner parameter in
Appendix C
Rest: 30 sec on spinner
Soft bake for SPR220 details
in Appendix C

21. Expose and
develop

Karl Suss MA6
Deep channel mask
(Mask-4)

Expose for 60s (385 mJ Dose).
Divided into 4 cycles with 30
sec hold time in between
Wait 1 hr before developing
Develop in MIF300 (TMAH)
for 300 sec
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22. DRIE high
resistant
channels and
vias

STS DRIE

Start with passivate layer and
end on etch. DRIE parameter
(Appendix c)

23. Strip
photoresist

24. DRIE high
resistant
channels and
vias

25. Etch oxide

Multiples of 5min etch with
alternative 30sec hold-cool in
between.
Etch: 335 µm

UV expose without mask.
Strip photoresist using PG
remover or
Acetone/IPA/MeOH/DI
STS DRIE

Multiples of 5min etch with
alternative 30sec hold-cool in
between.
Start with passivate layer and
end on etch. DRIE parameter
(Appendix c)

BOE bath

Etch: 70 µm

6:1 BOE solution etch until
chambers de-wet(10-15 min)
DI rinse cycle
Dry with N 2

26. Anodic
bonding

T = 420ºC
V= 1100V
t = 5-10min
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APPENDIX F
CO-CULTURE DEVICE DESIGN-3 MASK
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CO-CULTURE DEVICE DESIGN-3 WAFER
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APPENDIX G
SELF SUSTAINING CELL CULTURE SYSTEM
Different gravity-fed flow systems were utilized in generating the required flow rate for cell culture
(chapter-3 figure-19) in this thesis. As a parallel project, I have designed a fluid control system that can be
developed into self-sustaining cell culture unit (Figure 36). Figure 36 illustrates a prototype of the cell
culture system useful to run multiple microfluidic devices in parallel. Fluid flow in this system is controlled
using a electronic controller unit (in-house design) and piezo pumps (Bartel’s mp6). Low flow rates (20100 µl/hr) can be achieved in the system by including external restriction tubing (Teflon tubing Figure 36
) or restriction channels on the microdevice (similar to design-3 in chapter -3 figure-5). All the components
in Figure 36 that come in contact with cell culture media can be autoclaved and reused.

Figure 36: Self-sustaining cell culture system.
A prototype of the cell culture system indicating the various component involved.
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Figure 37: Different components of self-suistaining cell culture system
a) Image indicating the internal layout and components of the designed electronic flow controller unit.
There are three microprocessor units (dotted red line) laid out on the breadboard connected to other
components (variable resistor, rotatory switch capacitors, e.t.c.) b) a schematic overview of how a
microprocessor (piezo pump controller) is connected to the other components c) a housing to hold the
connecting tubes and piezo pumps were designed and 3D printed d) an image of coculture device with 3D
printed inlet/ outlet bonded onto the glass e) a weak fluorescence of the differentiating MN in the cell
chamber.
Figure 37a represents the inside layout of the in-house designed electronic controller unit. The detailed
schematic representation in Figure 37b illustrates how the external components are connected to each
microprocessor. Figure 37c represents the designed and 3D printed housing to hold the piezo pump and
connected tubing in place and avoid any leaks.
A weak eGFP expression (Figure 37e) in the cell chamber indicates the successful differentiation of mESC
to MN using the self-sustaining cell culture unit. Though it is referred to as a self-sustaining unit, the
temperature and gas control system are not yet included in the prototype. For the differentiation experiment,
the whole unit was introduced into the incubator for maintaining media and device at 5% CO2 and 37o C
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and the electronic controller is left outside the incubator to modulate the flow control. The experiment was
halted as inlets/ outlets (Figure 37d) unbonded from the underlying glass. Overall, this simple experiment
has indicated it as a working prototype. With future optimization and changes in design, this can act as a
standalone cell culturing unit.
Overall, this thesis illustrates the use of microfluidic systems in drug assay/screening and developmental
neurobiology. With advancement in technology and with proper collaboration this tool (microfluidic cell
culture system) can be tuned according to the areas of interest.
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APPENDIX H

Article I: “A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin.”
Chennampally, P. et al. A microfluidic approach to rescue ALS motor neuron degeneration using
rapamycin. Sci Rep-uk 11, 18168 (2021).
Abstract: Transgenic mouse model expressing ALS phenotype was generated. Presence of cytosolic TDP43 aggregates were identified in the mutant motor neurons (ALS phenotype) with more than 80 % cell death
by 28 DIV. Rapamycin treatment was useful in clearing the aggregates and rescuing the MNs from
degeneration. A microfluidic gradient generator was utilized to identify the ideal dosage (0.4-1.0 µM) range
in a 3D culture of ALS phenotype motor neurons and efficacy of rapamycin at various concentrations was
evaluated.
Contribution: Microdevice fabrication and characterization, on chip 3D motor neuron assays, 3D motor
neuron differentiation, data analysis, and writing manuscript.
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APPENDIX I
Article II: “Development-on-chip: in vitro neural tube patterning with a microfluidic device.”
Demers, C. J. et al. Development-on-chip: in vitro neural tube patterning with a microfluidic device. Dev
Camb Engl 143, 1884–92 (2016).
Abstract: A microfluidic platform capable of recreating the neural tube patterning was designed and
fabricated. A successful differentiation of MNs in the presence of gradients of Shh/purmorphamine and
retinoic acid in two different microfluidic system (a dual channel and four channel). Threshold RA
concentration was identified for successful MN generation. Generation of MNs in an opposing gradient of
Shh and BMP and under the influence of retinoic acid (four channel).
Contribution: Assisted in four channel device fabrication, four channel based experiments and data
collection.
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